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Poxviruses are double-stranded DNA viruses capable of causing disfiguring and deadly 
disease in a wide range of hosts, from insects to mammals. Orthopoxviruses (OPXV) encode many 
proteins that are not essential for viral replication, but are responsible for vast differences in 
pathogenesis. Of the >200 proteins in the prototypical OPXV vaccinia virus (VACV), many remain 
functionally cryptic. The objective of these studies was to understand how the VACV O1 protein 
functions by investigating cell-specific effects that may contribute to virulence. 
The O1L gene is expressed early as the O1 protein, a 78 kDa protein that lacked N-linked 
glycosylation. These data are the first to demonstrate the reduced ability of an O1 deletion mutant 
(∆O1) to induce cell migration compared to the parental VACV Western Reserve strain (VACV-
WR). ∆O1-infected cell monolayers also exhibited reduced plaque diameter and clearance in 
plaque foci. These observations indicated that O1 is a significant contributor to VACV cytopathic 
effects (CPE) in vitro, in agreement with published reports. The results reported herein are the first 
to describe an altered immunological response with ∆O1, as levels of anti-VACV immunoglobulin 
significantly increased with ∆O1 infection at a time point (seven days post-infection) when VACV-
WR induced VACV-specific antibody levels were comparable to sera from mock-infected mice. 
∆O1 was more immunogenic in an ex vivo antigen presentation assay, although mitogen-induced 
CD4
+
 T cell activation during ∆O1 infection was equivalent to VACV-WR infection. Surprisingly, 
of all the immune cell types tested, ∆O1 significantly differed from VACV-WR infection in the 
metabolic readout of only one cell type – RAW 264.7 macrophages. VACV-WR infected RAW 
264.7 macrophages were more metabolically active than ∆O1-infected cells at higher infectious 
doses, which may be indicative of a specialized niche for O1 function. Taken together, these data 
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Chapter 1: Introduction and Literature Review 
1.1 Research Overview 
 The overall purpose of the studies described in this thesis was to better understand how 
poxviruses cause disease in mammals. Poxviruses encode many proteins that promote virulence 
by manipulating the host immune system. The vaccinia virus O1 protein was hypothesized to be 
among a class of novel pox-specific immunoregulators; experiments performed to test this 
hypothesis are described herein. Identifying poxvirus proteins that manipulate the host immune 
response and determining their functional mechanisms provides knowledge of biological 
processes inherent to both poxviral pathogenesis and host immunity. Further appreciation of the 
poxviral-host systemic interactions generates new opportunities for a wide range of therapeutic 
interventions. 
1.2 Poxvirus biology  
1.2.1 Poxvirus classification  
Poxviridae are large, enveloped, double-stranded DNA viruses with linear genomes that 
can encode over 200 proteins. Poxviruses are classified into two subfamilies: Chordopoxvirinae 
(poxviruses that infect vertebrates) and Entemopoxvirinae (poxviruses that infect insects). 
Chordopoxvirinae are divided among nine genera, including four genera that infect humans – 
orthopoxvirus (OPXV), parapoxvirus, yatapoxvirus, and molluscipoxvirus (MCV). MCV and the 
OPXV variola virus (VARV: the causative agent of smallpox) are strictly human pathogens; the 
remaining viruses cause zoonoses. While MCV infections are currently more widespread (1), it 
is the OPXV [e.g. VARV, monkeypox virus (MPXV), and vaccinia virus (VACV)] infections 
that are among the most pathogenic for humans. 
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1.2.2 Vaccinia virus  
As the prototype OPXV, VACV is a valuable tool for investigating the biology of 
poxviruses and their mechanisms of pathogenicity. Structurally, VACV is composed of a 
dumbbell-shaped core flanked by two lateral bodies (Figure 1 A). The VACV core is enveloped 
by one or more lipid bilayers, resulting in two forms of infectious VACV. The most abundant 
form is the mature virus (MV), which has a single lipid bilayer studded with non-glycosylated 
viral proteins (2). The other infectious form is the enveloped virus (EV), which consists of MV 
particles with an additional viral membrane containing an alternate set of glycosylated viral and 
host proteins (3).  
The linear VACV genome is covalently closed by hairpin loops at both ends, and 
inverted terminal repeats flank the open reading frames (ORF) (4). There is an overall genomic 
organization to the > 200 ORFs encoded by VACV (Figure 1 B), wherein the most highly 
conserved poxviral genes (encoding replication machinery and structural proteins) are located in 
the central part of the genome [49 are common to all sequenced Poxviridae (5, 6)]. In contrast, 
genes with greater genetic variation tend to be located in the flanking ends of the genome and 
encode for a large proportion of virulence and immunomodulatory accessory genes. These genes 
are not essential for replication in tissue culture and can vary widely among viral strains and 
species (7). Pox genes can also be classified as early, intermediate, or late genes based upon their 
expression kinetics following infection, and recently a new class of genes – intermediate early – 
has also been proposed. [Figure 1C (8)]. Genes are classically named by their location on a 
HindIII restriction digest map (9). The HindIII digest of VACV (Copenhagen strain) has 15 
fragments (designated A-O in order of decreasing fragment size), with each ORF within a 
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fragment named using sequential numbers and relative orientation (10). Thus, the O1L gene is 
the first ORF in the HindIII “O” fragment, and the ORF reads to the left (L).  
1.2.3 Replication, morphogenesis, and dissemination 
The VACV infectious cycle (Figure 2) can be divided into seven phases (discussed as 
numbered): (1) entry, (2) uncoating, (3) DNA replication, (4) gene expression, (5) 
morphogenesis, (6) egress, and (7) spread. 1) VACV entry into a host cell is complex and can 
occur via multiple routes.  A single entry receptor for VACV has not been identified; the virus 
associates with various surface proteins prior to entry, including glycosaminoglycans (GAGs) 
and laminins (11). Entry into the cell is cell type and host dependent (12–14), and MV particles 
have been observed entering through macropinocytosis, endocytosis, apoptotic mimicry (12), 
and membrane fusion (15). Unlike most viruses, which may enter cells via a single protein-
receptor interaction, VACV has highly complex entry/fusion machinery, with at least 12 separate 
viral proteins forming a complex to facilitate fusion independently of binding (15). Since the 
entry/fusion machinery of VACV is only on the MV membrane (16), the EV outer envelope 
must dissociate before EV entry can occur (17).  
2) Upon entering the host cell, viral membranes are shed and the naked viral core is 
released into the cytoplasm. Microtubule machinery is hijacked by viral proteins to traffic the 
viral core further into the cell. Early mRNAs are transcribed within the cytoplasm, leading to 
uncoating of core and 3) subsequent DNA replication.  Unlike nearly all other DNA viruses, 
VACV encodes and packages its own enzymatic replication machinery, allowing for replication 
in a distinct cellular environment within the cytoplasm called the viral factory (2).  
4) VACV gene expression is temporally separated into three classes: early, intermediate, 
and late. Prior to viral DNA replication, early genes are expressed to produce proteins necessary 
4 
 
for DNA replication, as well as proteins that combat the host immune response (18). VACV 
DNA initiates replication by self-priming in the inverted terminal repeats through a mechanism 
that is still incompletely understood. The resultant DNA concatamers are cleaved by a viral 
resolvase enzyme into single-genome units (19). Subsequently, intermediate genes are expressed, 
resulting in a small number of intermediate genes, several of which are transcription factors for 
late gene expression. The late genes generally encode structural proteins needed for viral 
morphogenesis and the transcription machinery that must be packaged into nascent virions.   
5) During morphogenesis, MV particles are produced and processed within viral 
factories. A small proportion of MVs can be further transported through early endosomes and the 
trans-Golgi network, where the MV particles gain two additional membranes to form 
intracellular enveloped viruses (IEVs) (3). Again, VACV uses microtubules to transport itself 
within the cell, with IEVs being transported to the cell surface. 6) For the majority of virions, 
morphogenesis ends when MVs escape from the cell via cell lysis. However, in the case of IEVs, 
the outermost membrane fuses with the plasma membrane to expose an EV particle, termed cell 
associated EV (CEV) (3). Actin tail polymerization beneath the CEV is used to drive the virus 
into adjacent cells, or the virus is released as an EV. 7) EV particles are important for spread 
within the host, (20) and it is thought that the EV membrane functions to evade the host immune 
system, as it sequesters neutralizing antibody. Finally, cell-to-cell spread of VACV in tissue 
culture can occur in several ways. In cell culture, released EV can either infect adjacent cells or 
spread in a convection mediated, unidirectional manner to distal cells (21), forming the 






Figure 1. VACV structural and genomic organization 
(A) VACV virion structure: Transmission electron micrograph of the double membrane-
wrapped mature VACV virion (left); a cartoon depicts the virion structural components (right). 
Figure from (22) with permission from the publisher (Appendix B). (B) VACV genomic 
organization: The linear dsDNA VACV genome is ~200 kbp and flanked by terminal loops 
with inverted tandem repeats (ITR). Centrally located genes, generally essential for viral 
replication and morphogenesis, are more conserved, whereas termini-encoded ORFs are 
genetically variable and encode virulence factors. Adapted from (23) with permission from the 
publisher (Appendix B).  (C) Expression kinetics of VACV genome: Genes are classified 
according to when they are expressed upon infection. Colored boxes represent genomic islands 
with similar gene expression profiles.  Figure reproduced from (8) with permission from the 
publisher (Appendix B).  







Figure 2. VACV morphogenesis. 
(1) VACV virions attach to cells through varied mechanisms, and enter cells by membrane 
fusion. (2) Virus trafficking into cytoplasm is followed by virion uncoating and early gene 
transcription.  (3) DNA replication occurs within cytoplasmic viral factories, with subsequent 
intermediate and late gene expression. (4) Immature virions (IV) are packaged into intracellular 
mature virions (IMV), which are either released upon cell lysis, or (5) traffic through Golgi to 
form intracellular enveloped virus (IEV). (6) IEV are transported by microtubules to the cell 
membrane, where (7) cell associated virions (CEV) egress further via polymerized actin 
protrusions (green), releasing the extracellular enveloped virus (EEV).  
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1.3 Smallpox, vaccination, and emerging poxviruses 
1.3.1 A brief history of vaccination 
 The deliberate inoculation of smallpox (i.e. variolation) is thought to have been initiated 
by a Buddhist nun around 1000 AD. The practice of variolation spread from China to India and 
Turkey, but it was only in the late 1700s that this practice was implemented by European 
physicians. Several methods of variolation have been described, including the inhalation of 
powdered scabs or inoculation of pus into the skin. Lifelong immunity to smallpox was worth the 
slight chance of contracting smallpox (around 1%) from variolation. In 1796, Edward Jenner 
demonstrated that inoculation with infectious cowpox specimens also protected against 
smallpox. This form of inoculation, termed “vaccination,” (from the Latin vacca, for cow) 
appeared to be safer than variolation. While complications from the cross-protective vaccination 
method were far less than those of variolation, the protective effects lasted only 5-10 years. Later 
vaccination regimens indicated a regional preferences for either horsepox (France) or cowpox 
(England) specimens (24); ultimately, it was discovered that the Jenner vaccine was replaced by 
inoculation with the live VACV (25, 26). In 1939, the smallpox vaccines being used at the time 
were recognized not as CPXV, as originally thought, but a distinct OPXV species that was later 
designated VACV (27). VACV is a virological enigma, as it is the only vaccine to have been 
used to eradicate a disease, while its origin and natural host remain unknown. 
Although protective against OPXV, VACV can also be highly virulent in 
immunocompromised individuals, pregnant women, and individuals with inflammatory skin 
conditions like eczema, among others. If vaccinated with the currently stockpiled VACV 
vaccine, many individuals would have adverse and possibly fatal reactions, including: 
encephalitis, progressive vaccinia (uncontrolled spread of virus from vaccination site), eczema 
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vaccinatum (vaccinia lesions covering eczema prone regions) and generalized vaccinia (vaccinia 
lesions covering the body) (28, 29). VACV virulence makes its use contraindicated in up to 25% 
of the population (30–33), so vaccination is limited to military, first responders, and laboratory 
personnel. Research is ongoing to develop a more effective, safer VACV vaccine. 
1.3.2 The pathogenesis and eradication of smallpox  
Smallpox is one of the worst pandemics to decimate humanity, with an average fatality 
rate of ~30%. Indeed, in the 20
th
 century alone, smallpox deaths are estimated to have been ~500 
million (34). VARV infection begins when as few as 10 plaque-forming units (PFU) are 
absorbed into the respiratory or alimentary tracts (28, 35). VARV spreads from the initial site of 
infection to proximal draining lymph nodes. Over a 4 – 17 day latent period, VARV multiplies 
within the lymphatic phagocytic cells, primarily macrophages and monocytes. Following the 
conclusion of the latent period, VARV spreads from the lymph nodes into oropharyngeal mucous 
membranes and dermal capillaries. This brief viremia results in a prodrome stage, where 
symptoms include fever, malaise, and occasional vomiting. A rash appears 2 – 4 days after the 
prodromal symptoms, leading to the lesion formation in the mouth and subsequent centrifugal 
diffusion to the face, arms, and legs. The emerging lesions become pus filled and assume the 
distinctive “pock” mark: an opaque papule with a depressed center that eventually will burst, 
forming scab-covered lesions. Individuals are infectious from the onset of the rash until all scabs 
have fallen off and lesions heal. Approximately 30% of individuals exposed to VARV developed 
smallpox, with 5 – 40% succumbing to the disease (29). The major and minor strains of VARV 
accounted for the wide variance in morbidity, with the VARV major strain exhibiting more 
extensive morbidity and mortality rates from 10-40%. VARV minor strain mortality rates were 
usually <1% despite almost identical clinical presentation to the VARV major strain.  
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Historically, smallpox infections have been described as early as the 4
th
 century AD in 
China and in the 7
th
 century AD in India.  Due to the World Health Organization (WHO) mass 
vaccination campaign, the last natural incidence of smallpox occurred in 1977, followed by a 
laboratory incident shortly thereafter. The WHO declared smallpox successfully eradicated from 
nature in 1980 (36). Currently, VARV only officially exists in two laboratories in the United 
States and in Russia; however, the US government and many scientists still consider smallpox a 
threat, due to its potential use as a biowarfare agent. Indeed, VARV use as a bioweapon would 
be more effective than B. anthracis (anthrax) due to the efficient anthroponotic (human-human) 
transmission via an aerosol route, a largely susceptible (unvaccinated) population, and a high 
fatality rate.  
1.3.3 Studying an eradicated virus  
Several poxviruses currently present a credible threat to human health. MCV infections 
are common in young children, and recently MCV has also become a common sexually 
transmitted infection worldwide (1). The emergence of MPXV has dramatically increased in 
Africa, with one outbreak spreading to the USA in 2003 (37, 38). Although MCV infections are 
more prevalent, MPXV is currently the most significant threat to public health by a member of 
the Orthopoxvirus genus (39), because it is a viral zoonotic disease with an unverified reservoir 
(likely African rodents), has an indistinguishable clinical presentation to VARV infection, and a 
high case-fatality rate (37). Additionally, cowpox transmitted by rats recently caused an outbreak 
in a primate facility, killing 40% of animals, underscoring how dangerous zoonotic pox can be 
(40–42). Other pox zoonoses [buffalopox (43), tanapox (44), Cantagalo (45)] are also emerging, 
and it is thought by some to be occurring due to the decline in smallpox vaccinations (25, 38, 46, 
47).  Current literature on the phylogenetic relationships, ecology, and host range of OPXV 
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suggests that a VARV-like virus could emerge in the course of the natural adaptation of modern 
zoonotic OPXV, so continuing pox research is necessary.  
Poxviruses can also be used to treat diseases, as there are numerous biological properties 
that make them ideal for use as a vaccine vector (48–51).  Although there are still a number of 
poxvirus proteins of unknown function, there are a large number of well characterized poxvirus 
vectors that are in use or are being developed. These pox vectors are stable in both the physical 
particle and the genome, so they are suitable for accommodating large insertions of DNA for 
recombinant vaccines. Poxvirus vectors are also immunogenic (i.e. induce B cell and T cell 
responses), and are relatively easy to produce. Poxviruses are currently used as, or are being 
developed into, vaccines to treat malaria (52), rabies (48, 53), severe acute respiratory syndrome 
coronavirus (SARS-CoV) (34), Middle Eastern respiratory syndrome coronavirus (MERS-CoV) 
(54, 55), flu (52, 56), human immunodeficiency virus (HIV) (50, 57, 58), as well as cancer (59–
62). A more thorough characterization of the pox virulence proteins and host immune responses 
that promote adverse and fatal reactions to VACV vaccination could enhance development of 







Figure 3. History of smallpox vaccination and pathogenesis 
Figure 3 A depicts the timeline of human smallpox infections and highlights the history of 
VACV vaccination.  Reproduced from (23), with permission (see Appendix B). Figure 3 B) 
Smallpox morbidity (characteristic rash) and mortality rate (X) differ with inoculation route 
(respiratory, nasal, and dermal) and the ability of a host to control viral replication (lymphatic) 













1.4 Viral manipulation of the mammalian immune system 
1.4.1 Poxvirus-encoded mammalian homologs  
Mammalian hosts have developed complex defense mechanisms to control and clear 
virus infection, and protect against subsequent infections (Figure 4). Within the host 
environment, poxviruses are under selective pressure to evade the immune response and actively 
manipulate the host immune system in order to survive and replicate. Many poxviral genes that 
encode immunomodulatory proteins have an origin in the host genome (18, 64–66), having been 
acquired as necessary defenses from their host environments over time. These genes were 
identified through their homology to host proteins; however, poxviruses have also developed 
unique mechanisms for suppressing host immunity (18). Poxviral immunomodulatory proteins 
facilitate infection by preventing, evading, and diminishing host immune responses. A number of 
strategies are employed (Figure 5), including secreting decoy cytokine or chemokine receptors 
(66, 67), regulating apoptosis (68–72), and preventing complement-mediated lysis (73, 74). 
These effective immune evasion strategies also contribute to viral host specificity (18, 68). The 
majority of immunomodulatory genes are expressed early during infection to provide the virus 
with a substantial defense against the host immune system (reviewed in 19). With few 
exceptions, the removal of one or more of these immunomodulatory genes from VACV results in 
a mutant virus that causes attenuated disease in animals (44, 51). 
1.4.2 Poxviral modulators of antibody production 
Both the innate (75–78) and the adaptive (18, 79–81) immune responses are critical for 
controlling primary poxvirus infection (Figure 4) (18, 64, 69, 78). Furthermore, the successful 
use of poxvirus vaccines highlights the critical role of the adaptive immune response in 
controlling subsequent pox exposure events. The production of antibody by B cells is essential 
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for survival during primary pox infection, as it is one of the principal means of clearing 
poxviruses and inhibiting viral replication (80–82). The humoral response is the longest lasting, 
most effective means of preventing a secondary poxvirus infection (81). Thus, VACV may 
employ several direct approaches that reduce antibody production, including infecting B cells 
(82–84), manipulating intracellular signal transduction (85–91), and inhibiting regulatory 
cytokine production (77, 78, 85, 88, 92).  
CD4
+
 T cells also play a critical role during acute poxvirus infection by stimulating 
cytolytic T cells to clear virus (76, 82, 93) and helping B cells produce virus neutralizing 
antibody (76, 80, 94). Furthermore, CD4
+
 T cell help is necessary for B cell affinity maturation 
to produce high-affinity antibodies (25, 93). When CD4
+
 T cells are ablated during a poxvirus  
infection, there is a marked reduction in memory B cells, and a subsequent reduction in virus-
specific IgG and neutralizing antibody titers (76, 93, 95). However, it is not well understood 
whether VACV can act directly within CD4
+
 T cells to reduce their ability to help B cells 
generate high antibody titers during VACV infection. Suppressing the humoral immune response 
would be advantageous for virus survival, so identifying and understanding any contributing 
virulence factors is important. 
1.4.3 Inhibiting antigen presentation 
Poxviruses encode immunosuppressive proteins that are able to suppress T cell activation 
(77, 96), major histocompatibility complex I and II (MHC I and MHC II) molecules (97, 98) and 
anti-viral cytokines (IFN, TNF)(18) produced by CD4
+
 T cells in the early stages of natural pox 
infection. Prior studies have employed antigen presentation assays to understand basic biological 
interactions of the host immune responses in the context of viral pathogenesis during VACV 
infection (84, 97–99). Antigen presentation can be studied using splenocytes, which contain T 
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cells and a variety of antigen presentation cells (APCs: macrophages, dendritic cells, B cells). T 
cells become activated when the T cell receptor (TCR) recognizes its cognate antigen by 
interacting with MHC II on the surface of APCs. The activation state of T cells can be further 
modulated by APC co-stimulatory molecules. When T cells are activated they produce various 
lymphokines, including interleukin-2 (IL-2). Since production of IL-2 changes depending on the 
activation state of T cells, IL-2 is one measure of antigen-dependent T cell activation (84, 98, 
99). Thus, splenocytes from mice with TCR specific for a single cognate peptide can be used as a 
source of antigen-specific T cells to measure T cell activation, which is assessed by a cell 
proliferation bioassay using IL-2 dependent T cell lines. By employing antigen presentation 
assays, it is possible to then dissect intra- and intercellular mechanisms involved in adaptive 
immunity. Since a number of viral immunomodulatory strategies have previously been 
determined using antigen presentation assays (77, 84, 98–100), it may be possible to uncover 
novel cell-specific mechanism(s) that VACV employs to regulate host immunity. 
1.4.4 Other immunomodulatory strategies 
VACV primarily targets monocytes (101) and the innate APCs [e.g. dendritic cells (DCs) and 
macrophages] that are necessary for initiating adaptive immune responses. VACV has recently 
been shown to productively infect M1 and M2 primary human monocyte derived macrophages 
(MDM) polarized in culture (102). This is surprising, given earlier reports that VACV infection 
of macrophages is abortive (75, 103). Byrd et al. demonstrated that VACV productively infects 
primary macrophages, with higher viral loads produced by infection of anti-inflammatory M2 
polarized macrophages (102). VACV replication within M2 macrophages resulted mainly in EV, 
the virion subset that mediates long-range dissemination in hosts. In contrast to the detection of 
EV in supernatants by Byrd, et al. (102), prior reports only assessed VACV CEV from 
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macrophage lysates, so the lack of EV detection could be construed as an abortive infection 
(103). VACV replication was also enhanced with upregulated ERK and AKT activity and was 
susceptible to IL-10 mediated suppression.  Furthermore, VACV-infected macrophages 
exhibited characteristic cellular protrusions and branching reminiscent of VACV-induced 
migration of BS-C-1 cells (discussed below), supporting theories that VACV-induced migration 
may be a mechanism of viral dissemination. The apparent tropism for the M2 subset is 
interesting, as M2 macrophages are found within tissues with high replicative capacity (e.g. 
ovaries and tumors) for which VACV is highly tropic. It will be important to determine if 
macrophages with a lower innate antiviral response are specifically targeted by VACV, and if 
production of EV within macrophages promotes dissemination to other tissues where VACV can 
replicate unimpeded by the immune system. Migration of VACV-infected macrophages would 
promote VACV dissemination as well. Finally, the influence of VACV infection on tumor 
resident macrophage behavior is an important consideration for the development of more 
effective oncolytic vectors. 
 DCs are required to survive primary poxvirus infection (104), so it is interesting that 
VACV infection induces differentiation of monocytes into DCs (105). VACV also directly 
infects immature and mature DCs; however, VACV is only able to produce early genes in those 
abortive infections (83). Still, these early genes are sufficient to suppress many DC functions, 
including antigen uptake (106) and presentation (98), migration (107), maturation (98, 108, 109), 
and cytokine secretion (77). Furthermore, VACV inhibition of APC function results indirectly in 
impaired antiviral cytokine secretion by T cells (98), as well as reduced antibody production 
(84). In an evolutionary context, it is possible that poxviruses acquired mechanisms to induce 
monocyte differentiation into DCs in order to spread within the host. With the advent of the 
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adaptive immune response, poxviruses may have subsequently acquired separate mechanism(s) 
to prevent further maturation of immunostimulatory DCs. Determining which specific pox 
protein(s) mediate immunosuppressive functions could be important for the future development 




Figure 4  
 
Figure 4.  Anti-VACV host immune response. 
Antiviral innate immune defenses activated by pattern recognition receptors inhibit viral 
replication and activate antigen presenting cells (APCs) to initiate adaptive immunity. APC 
secrete cytokines and chemokines to attract effector lymphocytes into infected tissues. APC 





 T cells, respectively. CD4
+
 T (TH) cells produce cytokines and 
costimulatory factors that help B cells produce high affinity anti-VACV antibody (functions 
listed above), as well as promote CD8
+
 (CTL) T cell activation, expansion, and effector 
functions. Once the humoral and adaptive immune responses clear VACV from the host, VACV-








Figure 5. VACV immunoregulatory proteins. 
A significant proportion of the VACV genome (~30%) is devoted to immunomodulatory 
proteins. The functional mechanisms of these proteins are broadly classified as virostealth 
(proteins that mask infection and reduce cell-mediated immunity, green), virotransducers 
(proteins that inhibit innate antiviral, cell and host tropism signaling pathways, red), and 
viromimetics [(proteins that mimic host immunosuppressive proteins (black), cytokines and 
chemokines (light blue), or their extracellular (purple) and surface receptors (dark blue)]. 





1.5 Cytopathic effects during virus infection  
1.5.1 An introduction to cytopathic effects (CPE) 
Cytopathic effects (CPE) are changes in host cell behavior and structure attributed to 
virus infection. Common CPEs include: cell lysis, apoptosis (programmed cell death), cell 
rounding, syncytia formation (i.e. cell-to-cell fusion), cell-clumping, blebbing, cell detachment, 
formation of cytoplasmic projections, actin polymerization, cell motility, cessation of contact-
inhibition, antigenic changes on the cell-surface, cell division, release of lysosomal contents and 
formation of inclusion bodies. While some viruses produce obvious CPE, other viruses cause 
minimal CPE, or in the case of Hepatitis B virus (HBV), CPE that is only apparent in 
immunocompromised hosts (111). Hereafter follows an introduction to VACV-induced CPE. 
1.5.2 Examples of VACV CPE  
VACV infection disrupts numerous cellular pathways, resulting in significant changes in 
cell morphology. For instance, confluent monolayers of adherent cell lines infected with VACV 
result in the formation of large, circular plaques. Plaque formation is caused by a combination of 
CPE and migration of infected cells (112). Poxvirus genes that affect plaque formation can be 
grouped into three categories. First, many poxvirus genes that are essential for virus replication 
also contribute to plaque formation (reviewed in 85). Second, plaque formation relies upon actin 
polymerization to spread of infectious EV on actin tails (reviewed in 54). A third group of genes 
is required for normal plaque morphology and size but are not high contributors to virus output 
in vitro (112). Loss of proteins involved in 1) morphogenesis, 2) intracellular transport of IMV, 




VACV mutants with reduced plaque size or altered plaque morphology typically alter 
virulence. Examples in the third category include: C16 and B14 proteins, both of whose 
functions are required for normal plaque size and for virulence (114, 115). VACV proteins C2 
and A55 have been also shown to alter viral plaque morphology, because infections with mutants 
lacking either protein produced fewer cellular projections and lacked the characteristic Ca
2+
-
independent adhesion of VACV-infected cells (116–118). Identifying and understanding how the 
third group of plaque phenotype regulatory proteins functions may reveal novel pox virulence 
mechanisms which contribute to disease. Plaque size is positively correlated with case fatality 
rates for VARV isolates (119), which has supported the conventional view that changes in 
plaque morphology will be mirrored by in vivo changes to virus replication, spread and/or 
virulence. 
1.5.3 VACV and cell migration 
As mentioned above, one virally-induced CPE is cellular migration. It has long been 
established that VACV infection induces migration of infected cells in culture (120, 121), and 
this behavior is reminiscent of the epithelial to mesenchymal transition (EMT) of oncogenic 
cells. VACV-induced cellular migration has been partially attributed to the F11 protein (122, 
123), and studies have shown that the F11 mechanism promotes VACV spread, both in vitro and 
in vivo (124). However, in regards to other functionally distinct areas of VAVC-induced 
migration previously described, the mechanism(s) employed by VACV to induce this CPE 
remains unclear. Interestingly, VACV infection promotes migration of monocytes (125) and DCs 
(107, 126). Enhanced DC migration is not unique to poxvirus infection (reviewed in 96), as 
Ebola (128) and HIV-1 (129) infections have also been shown to promote migration of partially 
matured DCs. In contrast, VACV also encodes chemokine homologues that impair directional 
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migration of NK cells (130) and leukocytes (69, 73). While cell migratory behaviors are 
demonstrably affected by VACV infection in vitro and in vivo, it is still not fully understood how 
VACV functions within different cell types alter cell migration patterns. 
1.6 Vaccinia virus O1L gene in the literature 
1.6.1 O1L gene conservation and protein characterization 
Expression of the O1L gene (conventionally called O1 when referring to the protein) has 
been shown to begin early and continue through the infection cycle (8, 89, 131). Incidentally, the 
majority of VACV immunoregulatory genes are also expressed early, in theory, to rapidly 
counteract host defenses (18) . One report suggests that the O1 protein is present in the MV 
(132); however,  it was not identified in other studies (133–136). It is unknown with which viral 
or host proteins O1 may interact, as a large yeast-two-hybrid study reported no interactions 
between O1 and other VACV proteins (137), and reports have yet to identify interactions with 
host proteins (reviewed in 111). A recent bioinformatics study proposed a unique mutation 
pattern within the O1L gene, and suggested that O1 may have been particularly important for 
promoting virulence as VARV emerged in humans (139). Understanding how VARV adapted to 
specifically infect humans is an area of ongoing interest, and identification of genetic hotspots 
that contributed to VARV anthroponotic speciation may be important for predicting future 
emergence of pox zoonoses. 
It has been hypothesized that the poxvirus genome contains immunomodulatory proteins 
that are highly conserved in mammalian-tropic pox, with relative genetic conservation 
diminishing as viruses diverge into non-mammalian tropic pox, to the point where there is little 
to no homology with non-pox proteins. If these proteins are not essential for viral replication and 
are not related to any known proteins (pox or otherwise), the theoretical implications are that 1) 
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the proteins do not have an obvious host origin, and 2) poxviruses developed unique functions in 
a manner divergent from closely related viruses (like herpesviruses); of these pox-specific 
functions, some may be conserved to combat the mammalian adaptive immune system. Thus far, 
this hypothesis has led to the identification of several genes, one of which is immunosuppressive, 
A35 (84, 140–142). The studies discussed hereafter were initiated to determine whether another 
of these identified genes, O1L, modifies immune responses in a manner unique to poxviruses. 
1.6.2 Antigenic characteristics 





 T-lymphocytes (131, 143–145). In a VACV proteome-wide screen, an assay detecting 
secreted Th1 and Th2 signature cytokines showed that O1 was among the top Th1 targets, as O1 
peptides were able to restimulate both IL-2 and IFN-γ production by splenocytes from VACV-
WR–infected mice (146). O1 peptides were also identified among a screen of HLA-A and HLA-
B binding epitopes as immunogenic, although the immunogenicity of the O1-encoded peptides 
were either subdominant or cryptic (143). In that report, Assarsson speculated that subdominant 
T cells may be depleted, tolerized, or impaired in the course of an antiviral immune response to 
dominant epitopes. Thus, it is possible that immune responses against O1 epitopes may be 
reduced in favor of a stronger response to more immunostimulatory VACV epitopes. 
Reports indicate that O1 may be a prominent target of B lymphocytes as well (147, 148). 
In a serological screening targeting VACV proteins expressed individually in eukaryotic vectors,  
O1 was identified among 19 other VACV proteins as an immunodominant antibody target by 
sera from vaccinated C57BL/6 mice (148).  Additionally, O1 was identified among other VACV 
proteins that elicited a robust antibody response in Dryvax- and ACAM2000-vaccinated 
individuals (147). Thus, O1-specific antibody could be an important biomarker of VACV 
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immunity. Taken together, these data suggest that O1 is an important target of the adaptive 
immune response to VACV. However, the question of whether the immune system can impede 
the function of O1 is still outstanding.  
1.6.3 O1L and VACV CPE 
O1L has recently been identified as another VACV gene that influences plaque 
morphology in a study using the Chorioallantois Vaccinia Ankara (CVA) and Modified Vaccinia 
virus Ankara (MVA) strains (89). Due to a combination of missing and fragmented genes, MVA 
fails to replicate on most mammalian cell lines (149, 150). By reinserting fractured or missing 
genes, it is possible to generate recombinant MVAs with improved replication in some 
mammalian cells (151). Since the O1L gene is fractured in MVA, Schweneker et al. inserted the 
full-length O1L gene into MVA in an attempt to restore MVA replication (89). While this O1L 
reinsertion was associated with significant changes in plaque morphology, replication did not 
significantly improve in vitro. Additionally, when O1 was removed from CVA (CVA-∆O1), 
plaque sizes were 30 – 50% smaller than parental CVA in human epithelial kidney cells. 
Differences in plaque phenotype are often indicative of roles in replication, spread, and host 
range/cell tropism, although new evidence suggests there may be VACV proteins that affect 
plaque size without affecting any of the former life cycle functions (112). Since the contribution 
of O1 to VACV replication and spread are still tenuous at best, it may be possible that O1 is 
among this novel class of proteins for which a functional link to plaque phenotype has yet to be 
established. 
1.6.4 O1L alters MAPK signal transduction  
Mitogen-activated protein kinases (MAPK) are an important group of signaling mediators 
in the cell. The conserved signaling cascade consists of three sequentially activated kinases: a 
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MAP kinase kinase kinase (MEKK), a MAP kinase kinase (MEK), and a MAP kinase (MAPK). 
The mitogen activated protein kinase/extracellular signal regulated kinase 1/2 (MAPK/ERK) 
pathway plays a critical role in transmission of mitogenic and survival signals in response to a 
variety of extracellular stimuli. Since cell survival is vital for efficient virus multiplication, it is 
not surprising that many viruses, including VACV, manipulate this pathway.  
MAPK signaling cascades are still not completely characterized in the context of OPXV 
infections. This is unsurprising, given that basal MAPK activation varies with cell type, and 
OPXV manipulation of signaling cascades varies among species and strains. It is known that  
VACV infection triggers the MEK/ERK signaling cascade through the epidermal growth factor 
receptor (EGFR) which promotes infection; the disruption of these pathways results in decreased 
viral protein expression, DNA replication, and VACV multiplication (85). The C11 protein, also 
known as Vaccinia growth factor (VGF) has homology to human epithelial growth factor (EGF) 
and transforming growth factor β (TGFβ). C11 initiates a mitogenic signal that induces the early 
activation of ERK, but it is not necessary to sustain ERK activation or its downstream effects. 
Sustained ERK activation enhances cell proliferation in some cell lines, creating a productive 
environment for VACV replication. While the exact mechanism is still not fully characterized, 
some reports link proliferative effects of C11-mediated ERK activation to the proto-oncogene c-
fos (88). On the other hand, since c-fos transcription also increased with ∆C11 infection, other 
VACV protein(s) may be implicated in inducing c-fos activity. C11 also activates the 
EGF/interferon (IFN)-responsive Cip1 protein in cells expressing high levels of EGFR, resulting 
in cell cycle arrest (152). Interestingly, Cip1 is also thought to promote cell motility (153), but 
this has not been investigated in context of VACV infection. C11 functionally synergizes with a 
number of VACV proteins, including F1, which in turn suppresses apoptosis (154, 155). It is 
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clear that VACV manipulation of ERK signal transduction though C11 activation of EGFR 
results in a myriad of downstream effects that are not limited to viral replication, since numerous 
genes cooperate with C11 to promote ERK activation. However, only C11 has been shown to 
significantly enhance VACV replication through ERK manipulation in cell culture. Overall, 
C11-activated ERK may result in any number of effects depending upon the cell type, so the 
functional relevance in vivo will need to be carefully dissected in the future.   
O1 has recently been implicated in modulating the Raf-MEK-ERK signal transduction 
pathway (89). Schweneker reported that CVA-∆O1 infection reduced phosphorylation of c-RAF, 
MEK, and ERK1/ERK2, with no effects on JAK, FAK, AKT, or PI3K kinases. This indicates 
that O1 may function upstream of RAF, resulting in ERK activity that could indirectly influence 
any number of cellular processes, including cell proliferation (156), apoptosis, cytokine 
production, angiogenesis (157), cell polarity (158), and migration (159). While the reduction in 
CVA-∆O1 plaque size described above was partially attributed to the reduction in ERK 
signaling, the size of plaques treated with an ERK inhibitor were reduced similarly in both CVA 
and CVA-∆O1, with CVA-∆O1 plaque diameter again reduced by 30% compared to CVA. This 
suggests that the effects on plaque size are not entirely attributable to O1 stimulation of ERK 
activity.  
Importantly, since threshold ERK activity varies widely among cell types, it is likely that 
the function of O1 in an immortalized cell line does not accurately reflect viral effects in vivo. 
Furthermore, while prior studies have provided valuable insight into how viral manipulation of 
ERK signal transduction promotes virus infection and survival in the host, the associated 
mechanisms are vastly different. ERK manipulation may promote viral entry, expand host range, 
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and/or inhibit antiviral factors depending on the virus, host, and even cell type. Thus, the 
functional significance of upregulated MAPK signal transduction remains elusive.  
1.6.5 O1L contributes significantly to VACV virulence in mice 
Multiple studies have demonstrated that O1 and its orthologs are not essential for viral 
replication (89, 160–163), and reinsertion of O1 into MVA (where the gene is truncated) proved 
insufficient to restore wild type levels of viral replication in mammalian cells (89). However, O1 
was shown to be a significant contributor to VACV virulence in mice (89), observations that 
have been independently documented elsewhere [Wilkinson, unpublished; and (164)].  
Schweneker et al. reported that BALB/c mice (H2
d





 PFU/mouse) exhibited significantly reduced morbidity, and mortality rates were 80% lower 
than CVA-infected mice. A preliminary study by Wilkinson (unpublished) demonstrated similar 
effects in C57BL/6 mice infected with ∆O1 and the parental VACV-WR strain. In both studies, 
no differences were reported in viral titers of murine lungs, indicating that O1 is unlikely to 
influence VACV replication. On the other hand, Schweneker reported that CVA titers were 
higher than CVA-∆O1 in distal organs (ovaries), but only significantly differed six days post-
infection. Since VACV preferentially infects ovaries (165), high titers six days post-infection are 
not surprising. Given no differences in viral replication in vitro and in murine lungs, differences 
in ovary titers six days post-infection may indicate either: 1) enhanced tropism of CVA for 
ovarian tissue; 2) a delay in CVA clearance; or 3) a defect in CVA-∆O1 dissemination. None of 
these are mutually exclusive. Since an intact humoral immune response is required to control 
VACV dissemination (166), a defect in either CD4
+
 T cell activity or antibody levels (or both) 
during CVA infection would allow uncontrolled dissemination and prolonged presence within 
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Figure 6. ERK/MAPK signal transduction and putative O1 mechanism 
The mitogen activated protein kinase (MAPK) signal cascade is activated by ligation of various 
cell surface receptors, including the extracellular growth factor (EGF) receptor (EGFR). 
Activation of the extracellular signal regulated kinase (ERK) MAPK cascade through EGFR 
results in cellular functions (e.g. gene transcription, cell growth and proliferation, and cell 
survival) that can be further modified by simultaneous signaling through alternate surface 
molecules (i.e. integrins). The VACV C11 protein is a viral growth factor (VGF) homolog of 
EGF. VGF activates the ERK MAPK cascade, which enhances VACV multiplication by 
promoting cellular proliferation. The VACV O1 protein purportedly functions downstream of 
VGF to sustain ERK signaling activated through RAF and MEK (89). Although the exact 
mechanism of O1 is unknown, sustaining activation of ERK could occur through 1) enhancing 
upstream stimulators of RAF (e.g. RAS, SOS); 2) directly activating RAF; or 3) inhibiting 
negative regulators of ERK (e.g. MKP). O1 modulation of the RAF/MEK/ERK cascade has 




1.7 Project Aims and Hypotheses  
The overall aim of this project was to understand how the VACV O1 protein promotes 
virulence in mice, as attaining better insight into O1-specific mechanisms that enhance VACV 
survival of the immune response may have implications for biotherapeutic applications. Since 
viral modulation of signal transduction molecules can cause varied effects among hosts and 
immune cell types, consistency of O1 effects were evaluated across various immune and cultured 
cell types. Additionally, prior studies of non-essential VACV proteins that contribute to plaque 
morphology have revealed unique virus-host interactions, some of which influence the host 
immune response. Therefore, the effects of O1 on VACV-induced CPE was also examined   
Finally, since structural data on the O1 protein has been limited to sequence analysis predictions, 
the structural characteristics of the O1 protein were elucidated in order to gain insight into the 
functional mechanism of this protein. 
Thus, experiments were undertaken to test the hypotheses that O1:  
1) Influences the host immune system (Chapter 3) 
2) Functions differently in alternate cell types (Chapter 4) 
3) Alters VACV CPE other than plaque phenotype (Chapter 4) 
4) Has novel protein characteristics (e.g. size, modifications, homology, expression kinetics) 
(Chapter 4) 
If these hypotheses are supported, this would reveal (a) mechanism(s) whereby O1 functions in a 
novel manner to influence the host immune response to promote virulence. The functional 
mechanism(s) could be further delineated in vitro if alterations in cell-specific behavior are noted 
in ∆O1 compared to VACV, and if any cell-specific functions are influenced by the unique 
composition of the O1 protein.  
 
 
Chapter 2. Materials and Methods 
2.1 Virological methods 
2.1.1 Cell lines and culture conditions 
Mammalian cell lines used included: BS-C-1 green monkey kidney cells, RAW 264.7 
murine macrophage cell line,  1153 B lymphocytes and B04 T lymphocytes [both HEL peptide-
specific murine cell lines previously obtained from the Janice Blum laboratory (167)], cytotoxic 
T lymphocyte line (CTLL), Jurkat human T lymphocyte cell line, and HeLa human immortalized 
ovarian cell line (kind gifts of Dr. Isabelle Lemasson). RAW 264.7 cells were cultured using 
Dulbecco’s modified Eagle’s medium (DMEM). BS-C-1 and HeLa cells were cultured in 
modified Eagle’s medium (MEM), and all lymphocyte cell lines were cultured in Roswell Park 
Memorial Institute (RPMI) media. All media were completed by supplementation with 10% fetal 
bovine serum (FBS), 2 mM glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 50 
μM beta-mercaptoethanol. IL-2 dependent CTLL T cell lines were grown in complete RPMI 
(cRPMI) supplemented with a 0.5% dilution of IL-2 containing supernatants (produced by Sf9 
insect cell culture infected with IL-2 expressing-baculovirus, a kind gift from Dr. Mark Mannie). 
Bone marrow derived dendritic cells (BMDC) were obtained by harvesting bone marrow and 
culturing for 6-8 days in cRPMI supplemented with granulocyte-macrophage colony stimulating 
factor (GM-CSF, 1.5% Sf9 supernatant dilution). All cell lines were cultured at 37˚C in 5% CO2 
atmosphere conditions.  
2.1.2 Viruses, propagation, and purification 
Vaccinia virus Western Reserve strain (VACV-WR) was used throughout as the wild-
type (O1-expressing) virus. O1L deletion mutants (∆O1) were constructed previously (168) by 
homologous recombination of the O1L gene with an enhanced green fluorescent protein (eGFP) 
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marker. O1 deletion mutants (∆O1-1A1 and ∆O1-3A2) were independently selected and 
propagated, and both ∆O1 viruses were used throughout experiments to confirm ∆O1 
phenotypes. For virus propagation, BS-C-1 cells were grown to desired confluence (80-90%); 
viruses were diluted in cMEM to desired multiplicity of infection (MOI), and incubated for 2-3 
days at 37˚C. VACV-infected cell lysates were collected and stored at -80˚C for subsequent 
infections. Crude lysates were purified via sucrose gradient centrifugation prior to use in all 
animal infection and immunological assays. 
2.2 Animals and reagents 
2.2.1 Mouse infections 
All animal experiments described herein were approved by the East Carolina University 
Animal Care and Use Committee and performed in an AALAC accredited facility.  For analysis 
of VACV immunological effects, BALB/c and C57BL/6 mice were purchased from Charles 
River. To assess the effects of O1 on the murine immune system, BALB/c mice (n = 5) were 
intranasally administered aliquots (18 μL total, 9 μL/nares) of either VACV-WR, one of the ∆O1 
viruses (∆O1-1A1 or ∆O1-3A2), or were mock-infected with phosphate buffered saline (PBS). 




 PFU/mouse, depending on the experiment, and virus 
titers were determined on the day of challenge to confirm infectious dose. Weight and signs of 
illness were monitored daily, and mice were euthanized by isoflurane overdose at the end of the 
study, or if initial body weight decreased by 20%. Spleens and blood were harvested for ELISA 
and ELISPOT analysis. For antigen presentation assays, spleens were obtained post-mortem 
from naïve mice [B6, FOXP3-IRES-GFP knock-in (FIG) mice (B6.Cg-Foxp3
tm2Tch
/J) were 
crossed with MOG35-55 specific TCR transgenic 2D2 mice (Tcra2D2,Tcrb2D21Kuch/J) to obtain 




Polyclonal rabbit sera (Genemed Synthesis) were raised against two synthetic O1 peptide 
sequences (AA351-371 and AA393-414), and used as a primary antibody for immunoblot analysis 
(1:1000 dilution). An unconjugated anti-mouse IgG-IgM-IgA (H+L, Sigma) was used for 
ELISA. Fluorescently conjugated primary antibodies used for the studies described herein 
included: PE-CF594 conjugated anti-CD69 (BD Horizon) BV421 conjugated anti-CD69 (BD 
Horizon), and PE-Cy7 conjugated anti-CD4. Secondary antibodies included: alkaline 
phosphatase-conjugated anti-rabbit IgG (Sigma), and alkaline phosphatase-conjugated anti-
mouse IgG-IgM (H+L, Invitrogen).  
2.3 Analysis of viral protein expression and post-translational modification 
2.3.1 SDS-PAGE analysis 
Proteins from infected cells were harvested in sodium dodecyl sulfate (SDS)-reducing 
sample buffer (62.5 mM Tris-HCl, 0.25 M glycerol, 2% SDS, 0.01% [wt/vol] bromophenol blue, 
12.5% [vol/vol] β-mercaptoethanol) and boiled at 95°C for 5 min. Proteins were separated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using Tris-HEPES gradient gel (4-20%, 
Thermo) or prepared Tris-glycine gel (resolving gel of 8% acrylamide solution, 0.375 M Tris-
HCl, pH 8.8, 0.1% [wt/ vol] SDS, 0.1% ammonium persulfate (APS), and 0.1% N,N,N=,N=-
tetramethylethylenediamine [TEMED]; stacking gel of 4% acrylamide solution [37.5:1], 0.375 
M Tris-HCl, pH 6.8, 0.1% [wt/vol] SDS, 0.1% APS, and 0.1% TEMED). Coomassie Blue R-250 
(Sigma: 0.5 % [wt/vol] prepared in 50% methanol with 10% acetic acid) staining was used for 
visualization of total protein. 
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2.3.2 Immunoblot for protein expression and size analysis 
Proteins samples were resolved via SDS-PAGE (as described above) and transferred (200 
mA, 2h) to PVDF membranes using low methanol transfer buffer (12% methanol, 0.1% SDS). 
Membranes were probed with anti-O1 rabbit sera as primary antibody diluted in PBS- milk (5% 
[wt/vol] skim milk in PBS with 0.1% Tween 20) for 30 min. The membrane was washed three 
times in PBS-milk and probed with alkaline phosphatase conjugated secondary antibodies  for 30 
min. Immunoreactive protein bands were visualized by incubating membranes in alkaline 
phosphatase substrate (Western Blue, Promega) for 30-45 minutes (25˚C). 
2.3.3 Glycosidase assay for analysis of N-linked glycosylation 
To determine whether O1 is N-linked glycosylated, HeLa cells were infected (MOI =10) 
for 18 hours. Whole cell lysates were digested for 3-5 hours using either endoglycosidase H 
(Endo H, Promega) or peptide N glycosidase F (PNGase F, Promega). SDS-PAGE was 
performed under denaturing conditions as described above. Immunoblots were developed using 
anti-O1 sera or polyclonal anti-B5R sera (BEI Resources) to detect a known vaccinia N-linked 
glycosylated protein (B5R) as a positive control for enzymatic degradation. 
2.4 Analysis of antiviral immune responses in vivo 
2.4.1 ELISA for in vivo total anti-VACV immunoglobulin  
Enzyme-linked immunosorbant assay 96 well plates (Immulon H2B, Thermo Electron) 
were coated with ELISA coating buffer (ddH2O, 1% H2BO4, 0.7% NaCl, pH 8.6) containing 
VACV-WR lysates (10
5
 PFU/well) and incubated overnight at 4˚C. Plates were blocked (PBS, 
2% FBS, 0.1% NaN3) at room temperature for 30 min, washed three times (PBS, 0.02% Tween 
20, 0.1% NaN3), and titrations of sera obtained from each infected mouse were added. Plates 
were incubated 1.5 hours at room temperature and washed again before the addition of the 
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secondary antibodies (alkaline phosphatase-conjugated goat anti-mouse IgM-IgA-IgG and 
alkaline phosphatase-conjugated goat anti-mouse IgG [Southern Biotech]). After a 2 hour 
incubation period, plates were washed three times, developed (alkaline phosphatase substrate kit; 
Bio-Rad), and the colored product was analyzed by spectrophotometric detection of absorbance 
at 405 nm. 
2.4.2 ELISpot 
Anti-mouse IFNγ antibodies (1:500 dilution) were used to coat 96 well plates (1X PBS, 
pH 7.2) and incubated overnight.  Plates were blocked with blocking buffer (2% FBS in PBS, 
0.1% NaN3) and washed with PBS prior to the addition of mouse splenocytes. Splenocytes were 
then incubated in cRPMI media for 40 hours with VACV-WR infected cell lysates (MOI = 1) to 
stimulate production of IFNγ. After the removal of splenocytes and virus with wash buffer (PBS 
with 0.05% Tween 20, 0.1% NaN3), plates were then blocked with biotinylated rat anti-mouse 
IFNγ (1:250 dilution) and incubated for 2 hours in a humidified chamber. Plates were washed 
again with wash buffer and blocked with Streptavidin AP. Following a 1 hour incubation and 
washing, plates were overlayed with BCIP in AMP buffer and agarose to obtain countable blue 
spots upon development. 
2.5 Ex vivo immunological assays 
2.5.1 Purification and activation of T cells 
Splenocytes were isolated from C57BL/6 mice and infected for 3 hours (MOI = 3 and 5) 
with VACV-WR, ∆O1 or mock (cRPMI), followed by treatment with concanavalin A (ConA, 5 
μg/mL) diluted in cRPMI to induce activation. Alternately, CD4
+ 
T cells were purified via 
positive selection using CD4
+
 T cell magnetic beads (EasySep), infected and activated with 
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ConA as before. Cells were monitored microscopically for blastogenesis for 24 - 48 hours prior 
to flow cytometric experiments assessing activation markers.  
2.5.2 Purification and activation of B cells 
Splenocytes were isolated from C57BL/6 mice and purified via negative selection using 
Pan-B cell magnetic bead kit (EasySep). Cells were infected for 3 hours (MOI = 5) with VACV-
WR, ∆O1 or mock (cRPMI) and plated in 96 well plates (1x10
5
 cells/well). Appropriate groups 
were treated with lipopolysaccharide (LPS, Sigma: 1-10 μg/mL) diluted in cRPMI. For ex vivo 
antibody production assays, supernatants (100 μL) were collected from plates that had incubated 
for either seven or 12 days post-infection. 
2.5.3 Antigen presentation assays 
2D2-FIG mice are TCR transgenic mice with self-reactive TCR that are specific for 
myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35-55) and cross-reactive with the 
neurofilament medium (NEFM18-30) peptide (169, 170). 2D2-FIG splenocytes contain both APC 
and T cells specific for these antigens. Upon incubation of splenocytes with the antigenic 
peptide, splenic APC present antigen to activate T cells, which produce lymphoproliferative 
cytokines like IL-2. Splenocytes isolated from 2D2-FIG mice were cultured in 96 well plates 
(1x10
5
 cells/well) and infected with VACV-WR, ∆O1 (MOI = 1, 3h), or mock-infected (media) 
as a positive control. Cells were then pulsed with one of the cognate antigenic peptides [either 
MOG (5 μg/mL) or NEFM (1 μg/mL)] and supernatants were collected 24-96 hours post-
infection to determine levels of bioactive IL-2 via bioassay 
2.5.4 CTLL cell proliferation bioassay 
Antigen presentation was quantified using a bioassay measuring proliferation of IL-2 
dependent CTLL T cells. CTLL cells were washed with cRPMI twice to remove IL-2 within 
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culture media, and incubated in 96 well plates (5x10
4
 cells/well in 150 μL) for 24 hours. 
Supernatants (50 μL/well) from antigen presentation assays described above were added to 
CTLL cells, followed by 24 hours of incubation. MTS was added (10 μL/well) and absorbance 
was measured (492 nm) incrementally over 24 hours. 
2.5.5 ELISA for ex vivo antibody production 
Enzyme-linked immunosorbant assay 96 well plates (Immulon H2B, Thermo Electron) 
were coated with ELISA coating buffer (ddH2O, 1% H2BO4, 0.7% NaCl, pH 8.6) containing 
anti-mouse IgM-IgG-IgA (H+L, Invitrogen) and incubated overnight at 4˚C. Plates were blocked 
(PBS, 2% FBS, 0.1% NaN3) at room temperature for 30 min, washed three times (PBS, 0.02% 
Tween 20, 0.1% NaN3), and dilutions of supernatants obtained from ex vivo B cell activation 
culture were added. Plates were incubated 1.5 hours at room temperature and washed again 
before the addition of the secondary antibodies (alkaline phosphatase-conjugated goat anti-
mouse IgM-IgA-IgG ) After a 2 hour incubation period, plates were washed three times, 
developed (alkaline phosphatase substrate kit; Bio-Rad), and the colored product was analyzed 
by spectrophotometric detection of absorbance at 405 nm. 
2.5.6 Flow cytometric analysis 
Splenocytes were analyzed by flow cytometry for CD4
+
 T cell activation. Splenocytes 
(1x10
6
 cells/mL) or purified, activated T cells (1x10
6
 cells/mL) were fixed in 3% 
paraformaldehyde, washed, and incubated with an anti-Fc block (BD Pharmingen) to prevent 
non-specific binding of antibodies to Fc receptors. Fluorescently conjugated anti-mouse primary 
antibodies were incubated on ice for 1 hour, then washed and resuspended in flow buffer (PBS, 
2% FBS, 0.2% sodium azide). Samples were taken (10,000 events/group) on an LSR II flow 
cytometer (Becton Dickinson) and data were analyzed using FlowJo software. 
37 
 
2.6 Analysis of ∆O1 cytopathic effects (CPE) 
2.6.1 Plaque assays 
For plaque assays, confluent BS-C-1 monolayers were infected in duplicate using the 
methods describe above.  Viral doses added to wells were calculated to result in 50-100 
countable plaques per well. Following five 1:10 serial dilutions, appropriate virus dilutions were 
added to cell monolayers, and plaques were allowed to form 40 – 48 hours before fixation with 
crystal violet solution (0.1% in 20% ethanol). Viral titers were defined as plaque forming units 
per mL (PFU/mL) of initial virus solution, as determined by enumeration of plaques by 
independent blind observers. Plaques were photographed, and plaque diameters were calculated 
using Fiji software (10 plaques/virus) for statistical analysis.  
2.6.2 Wound-healing assay 
For wound-healing assays, confluent BS-C-1 monolayers grown in 6 well plates were 
serum-starved for 2 hours and then carefully scratched with a yellow 200 µl pipette tip to create a 
grid pattern. Immediately after scratching, cells were washed in PBS and infected in duplicate as 
described above. Monolayers were photographed at specified times post-infection, and fixed 
with crystal violet 24 – 48 hours post-scratch. For statistical analyses, cells migrating into 
scratched regions (five regions/well) were enumerated by two independent observers.   
2.6.3 MTS/PMS cytotoxicity assays 
The effects of O1 on the viability of various immune cell types [e.g. macrophages (RAW 
264.7 cell line), T cells (B04, Jurkat, CTLL lines and splenic primary cells), B cells (1153 line 
and splenic primary cells), and bone marrow derived dendritic cells (BMDC)] were examined. 
Cells were infected with VACV-WR or ∆O1 (MOI = 1, 5, and 10 PFU/cell), or mock-infected 
with media. Twenty-four hours post-infection, 10 μL of 3-(4, 5-dimethylthiazol-2-yl)-5-(3-
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazine methosulfate [MTS/PMS 
(2.0 mg/mL MTS and 0.1 mg/mL PMS)] was added to each well and the resultant colorimetric 
change was detected at 492 nm over designated intervals. 
2.7 Computational analysis 
The O1 peptide sequence (WR068, PDB: Q80HX1) was obtained from the NCBI 
database (https://www.ncbi.nlm.nih.gov/protein) and compared to peptide sequences using 
UniProt (http://www.uniprot.org). Protein domains were characterized using the InterPro 
database (http://www.ebi.ac.uk/interpro). Transmembrane regions were examined using the 
TMPred (embnet.vital-it.ch/software/TMPRED_form.html) and MINNOU servers 
(minnou.cchmc.org), and Signal P was used to predict the signal peptide sequence 
(http://cbs.dtu.dk/services/SignalP). O1 protein structural predictions were investigated using 
various programs on Protein Model Portal (http://www.proteinmodelportal.org), and Phyre2 
(www.sbg.bio.ig.ac.uk/phyre2) was used to render 3D models of O1 tertiary structure. 
2.8 Statistics 
For comparison of more than two conditions at a single point in time, one-way ANOVA 
was used with Tukey’s multiple comparison tests. For multiple comparisons of two or more 
groups, two-way ANOVA with replicates was employed. For comparison of two conditions, a 
two-tailed Student t test was used. The Data Analysis ToolPak in Microsoft Excel was employed 




Chapter 3. Immunogenicity during ∆O1 infection was increased 
compared to VACV-WR infection 
3.1 VACV-specific immunoglobulin levels increased in ∆O1-infected mice 
3.1.1 In vivo antibody levels were enhanced during ∆O1 infection 
Published reports have demonstrated that O1 contributes to VACV pathogenesis in mice 
(89), and it was hypothesized that O1 mediates virulence by interfering with the mammalian 
immune response. To investigate the effects of O1 upon the immune response, mice were 
infected with lower doses of VACV-WR or ∆O1 viruses [7 x 10
3
 PFU/mouse] to preclude the 
effects of systemic illness seen in infections with high doses (171). The specific anti-VACV 
antibody levels detected in sera collected seven days post-infection from VACV-WR infected 
mice were similar to levels of sera in mock-infected mice (Figure 7). Significantly greater 
quantities of anti-VACV antibody were detected in sera from ∆O1-infected mice. The 
diminished levels of total anti-VACV antibody in VACV-WR infection suggest that ∆O1 may be 





Figure 7. ∆O1 infection induced a stronger humoral response than VACV-WR in mice.  
BALB/c mice (n = 5) were infected intranasally (2 x 10
3 
PFU/mouse) with either VACV-WR 
(WR), ∆O1 (∆O1-1A1 or ∆O1-3A2,), or mock-infected (PBS). To quantify the VACV-specific 
antibody produced, serum isolated from each group seven days post-infection was analyzed by 
ELISA to detect VACV-specific IgM, IgG, and IgA antibodies. Experiments were performed 
three times, and the representative data shown are the average absorbance (OD 405 nm) of the 
serum titration from each group (± SEM). Two-way ANOVA and post-hoc Tukey’s assessments 
were performed to assess the statistical differences between VACV-WR and both ∆O1 mutants. 
Absorbance of both ∆O1-1A1 and ∆O1-3A2 groups were statistically greater than VACV-WR, 





3.1.2 Ex vivo antibody production reduced similarly by VACV and ∆O1 infection 
Antibody production was examined ex vivo to detect interactions occurring during 
VACV-WR infection that could result in reduced antibody levels. LPS stimulation of murine 
splenic B cells moderately increased (20-40%) ex vivo antibody levels in all infection groups 
above unstimulated levels (Figure 8). Infection with both viruses significantly reduced antibody 
levels compared to mock-infected cells, and reductions by VACV-WR and ∆O1 were equivalent. 
Because splenic-resident T cells and DC are instrumental in helping B cells produce antibody in 
vivo, whole splenocytes were infected as before and stimulated with LPS to induce antibody 
production (Figure 9). Results obtained seven days post-infection (Figure 9 A) were similar to 
those obtained using in purified B cells (i.e. LPS induced antibody production that was 
significantly reduced by infection with either virus). Because the background readings of 
unstimulated cells seemed high for these assays, splenic cultures were also allowed to incubate 
longer to ensure sufficient time for antibody production. However, total antibody detected on day 
12 (Figure 9 B) was diminished compared to seven days post-infection (Figure 9 A). Taken 
together, these data suggest that ex vivo assays of LPS-stimulated antibody production are not 
sufficient to understand how O1 influences antibody production. These data provide suggestive 
evidence that other mechanisms (e.g. cell types or functions) that are operative in vivo are likely 








Figure 8: VACV infection reduced LPS-induced immunoglobulin produced by purified 
mouse splenic B cells. 
B cells were isolated (Pan-B negative selection kit, EasySep) from C57BL/6 mouse splenocytes, 
were infected with either VACV-WR or ∆O1L-1A1, or remained uninfected (MOI = 3, 4 hours). 
Groups treated with LPS (10 µg/mL) to induce immunoglobulin production are depicted by 
black bars, and groups of unstimulated B cells are in white. Supernatants were harvested seven 
days post-infection and assayed via ELISA for total mouse antibody (IgG, IgM, IgA) production. 
OD readings are expressed as the mean (n = 3) ± standard deviation. Experiments were repeated 
twice, and representative data are depicted. * denotes statistical significant differences between 







Figure 9: VACV infection reduced ex vivo LPS-induced immunoglobulin produced by 
murine splenocytes. 
C57BL/6 mouse splenocytes were isolated and were infected with either VACV-WR or ∆O1-
1A1 or were not infected (mock) (MOI = 3, 4 hours).  Splenocytes were then treated with LPS 
(10 µg/mL) to induce immunoglobulin production. Supernatants harvested seven (Figure 9 A) 
and 12 (Figure 9 B) days post-infection were assayed via ELISA for total mouse antibody (IgG, 
M, A) production. Each assay was repeated twice, with similar results. OD readings of 
unstimulated splenocytes (white bars) and LPS-stimulated splenocytes (black bars) are expressed 
as the mean (n = 3) ± standard deviation * denotes statistical significant differences between 

















3.2 Equal VACV-specific interferon-γ produced by VACV-WR and ∆O1-
infected splenocytes 
To ascertain whether O1 had an effect on T lymphocytes during VACV infection, 
ELISpot assays of IFN-γ production were performed. Splenocytes from mice infected with 
VACV-WR, ∆O1, or mock-infected with saline were isolated, and stimulated with VACV-WR 
to reactivate VACV-specific T cells ex vivo, and IFN-γ was measured as a marker for 
reactivation. As shown in Figure 10, splenocytes from mock-infected mice do not produce IFN-
γ, indicating that mock-infected mice do not have recall responses to VACV, as T cells were not 
introduced to VACV in vivo. Splenocytes from mice infected with either VACV-WR or ∆O1 
produced equivalent levels of IFN-γ, which suggests that there were no detectable differences in 








Figure 10: VACV-specific IFN-γ production by VACV-WR and ∆O1 infected murine 
splenocytes was equivalent. 
Effector responses to VACV were quantified by assessing IFN-γ production in response to 
VACV-WR stimulation ex vivo. Splenocytes from VACV-WR, ∆O1 (∆O1-1A1 and ∆O1-3A2), 
and mock-infected BALB/c mice (n = 5/group) were isolated seven days post-infection, and 
stimulated with VACV-WR. IFN-γ producing cells were enumerated via ELISpot assay. 
Experiments were performed twice, with essentially equivalent results. The mean of each group 
(± SEM) are depicted, and a one-way ANOVA analysis revealed no statistically significant 




3.3 Ex vivo antigen presentation is enhanced during ∆O1 infection 
3.3.1 2D2-FIG antigen presentation assay 
Because ∆O1 infected mice generated enhanced levels of antibody, it was hypothesized 
that the O1 function may be immunosuppressive. Since B cells need T cell help for maximal 
VACV-specific antibody responses, the hypothesis was that lower antibody levels observed in 
vivo could be due to inferior priming of T cells at the level of antigen presentation. Since T cell 
recall responses were similar (Figure 10) during VACV-WR and ∆O1 infection, it was possible 
that differences in vivo may have been too small to distinguish. Alternately, it is likely that O1 
may have affected the helper T cell processes necessary for humoral, but not cellular, immunity. 
Thus, ex vivo antigen presentation assays were performed to determine how O1 influences 
immunological processes.  
2D2-FIG mouse splenocytes were isolated and infected with VACV-WR, ∆O1 or mock 
infected (media), and then stimulated with cognate antigens (MOG35-55 or NEFM18-30). 
Supernatants collected at various time points were added to IL-2 dependent CTLL T cell cultures 
to quantify bioactive lymphoproliferative cytokines produced in response to antigenic 
stimulation. Supernatants from 2D2-FIG antigen presentation assays promoted CTLL 
proliferation in peptide-stimulated groups (Figure 11). Supernatants from VACV infected 
groups significantly inhibited CTLL proliferation compared to mock-infected cells. Stimulation 
with MOG appears to have no effect on VACV-WR infected cells (Figure 11 A) whereas 
supernatants from NEFM treated, VACV-WR infected groups increased CTLL proliferation 
approximately 10% more than the unstimulated VACV-WR infected group (Figure 11 B). 
However, when cultured with supernatants from antigen stimulated ∆O1-infected groups, CTLL 
proliferation significantly increased. Although not quite to mock-infected levels, supernatants 
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from ∆O1 infections enhanced CTLL proliferation by 12 – 20% over VACV-WR groups, and 
these differences were statistically significant at 24 and 48 HPI. The reduced CTLL proliferation 
in response to supernatants from the VACV-WR infected, antigen-stimulated group indicate that 
some step in the antigen presentation process is significantly different during ∆O1 infection. 
Given the complexity of the antigen presentation process, these data provide a foundational step 
for the further work needed to determine which processes (e.g. antigen processing or 
presentation, TCR recognition and signaling, IL-2 gene transcription, etc.) may be influenced to 
a greater extent by VACV-WR compared to ∆O1 infection. 
3.3.2 CD4
+
 T cell activation 
Lymphoproliferative cytokines secreted in response to antigenic stimulation may be 
reduced if T cell activation is altered by VACV-WR infection. Therefore, the possibility was 
considered that antigen presentation would be reduced in VACV-WR infection if O1 directly 
affected T cell activation. To investigate this, splenocytes were isolated, infected with VACV-
WR or ∆O1, followed by treatment with ConA for 18-36 hours to induce T cell activation. Flow 
cytometry was used to measure surface expression of CD4 for helper T cells, as well as CD69, a 





 events present in the upper right quadrant of dot plots (Figure 12 A). Treatment 




 events, with the greatest increase in the 




 cells trended lower in 





 T cells (Figure 12 B). These experiments were also repeated using 
positively selected CD4
+
 T cells, with similar results (data not shown). Taken together, the 
equivalent activation of CD4
+
T cells during VACV-WR and ∆O1 infection suggests that O1 is 
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unlikely to directly interfere with mitogenic CD4
+
 T cell activation. Whether or not O1 directly 
interferes with the antigenic activation of CD4
+




Figure 11. CTLL proliferation was enhanced by antigen-stimulated ∆O1-infected 
supernatants.  
The antigen presentation process, culminating in IL-2 production, was assessed via CTLL cell 
proliferation assay. Splenocytes isolated from 2D2-FIG mice were infected (MOI = 1, 3h) with 
VACV-WR, ∆O1 (∆O1-1A1) or mock-infected (mock). Cells were pulsed with cognate antigens 
(Figure 11 A: MOG, 5 µg/mL; Figure 11 B: NEFM, 1 µg/mL), and supernatants were collected 
24-96 HPI. The IL-2 dependent CTLL T cell line was used to measure IL-2 in collected 
supernatants. CTLL cells were IL-2 depleted 24 h before addition of collected supernatants (50 -
100 µL). After 24 hr culture, MTS was added and OD read at 492 nm. Experiments were 
repeated twice, and data from 24 h post-infection is displayed. OD readings are expressed as the 
mean (n = 3) ± standard deviation. * denotes statistical significant differences between antigen-
treated, mock-infected cells and virus groups (black bars, one-way ANOVA, ρ ≤ 0.05.)  















Figure 12: ConA-induced CD4
+
 T cell activation was equal in VACV-WR and ∆O1 
infections.  
C57BL/6 mouse splenocytes were isolated, infected (MOI = 3) with VACV-WR or ∆O1 in 
duplicate, or mock infected (mock) for five hours before treatment with concanavalin A (ConA, 
10 µg/mL) to induce T cell activation. After 48 h, flow cytometry was performed to detect 




). Cells were gated to exclude debris, and plotted CD4 




 events (Figure 12 B). Data 
were analyzed via two-way ANOVA, and differences among ConA stimulated groups were not 



















Chapter 4. O1 protein expression and contribution to VACV CPE 
4.1 O1 sequence analysis 
The O1L gene (VACV Copenhagen strain designation) encodes the putative O1 protein 
(666 aa) which is predicted to be approximately 78 kDa. Since there are no reported O1-
homologous viral or mammalian proteins with known functions [phylogenetic analysis reviewed 
elsewhere (139)], comparisons could not be made to predict possible O1 function(s). Thus, 
software analyses were performed to assess biological composition of O1 to understand how its 
structure may influence function. The O1L gene is located within the central portion of the 
VACV genome, which contains a large proportion of genes that are necessary for viral 
replication and morphogenesis (23). The genes most proximal to O1L include DNA 
polymerases, DNA binding proteins, and viral core proteins (Figure 13 A). However, data from 
prior studies  (89, 168) do not support a role for O1 in viral replication or spread in cell culture or 
in vivo. In Figure 13 B, secondary structural domains of the O1 protein include a predicted 
transmembrane region (TMPred), two nuclear localization sequences (SwissProt), and five N-
linked glycosylation motifs (visual inspection of NxS/T sequences). Many peptide sequences in 
O1 are hydrophobic in nature (Figure 13 C), which could suggest membrane association or a 
tertiary folding pattern such that hydrophobic sequences are sequestered to reduce solvent 
accessibility. Ab initio 3D-rendering of the O1 peptide sequence (Figure 13 D, Phyre2) 
generated a protein with numerous alpha-helices, and several low structure regions. The 
structural homologs reported by Phyre2 (Table 1) exhibited low-levels of structural identity (7 – 
50%, with confidence ranging from 5.2 – 54.3 %). Several enzyme families were overly 
represented among the proteins identified (more than five hits in six different groups Table 1 A), 
and at least two structural domains were identified more than five different times (Table 1 B). 
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While this may be indicative of potential O1 functional orthologs, the low sequence identity 
suggests that the function of O1 may be completely novel. Future biochemical studies will be 
necessary to confirm whether the described peptide regions and structural motifs contribute to 













Figure 13. O1 sequence analysis 
Figure 13 A: The O1L gene sequence is depicted in context of proximal VACV genes. Figure 
13 B: Secondary sequence searches revealed predicted N-linked glycosylation sites (designated 
NxS/T motifs as marked below arrow), transmembrane region (TMPred software, denoted TM), 
and nuclear localization signals (NLS, SwissProt). Peptide regions selected for anti-rabbit sera 
generation are denoted P1 and P2. Figure 13 C: Plot of O1 sequence hydrophobicity depicts 
peak regions of hydrophobicity, including one transmembrane region also predicted by TMPred. 
Figure 13 D: A model of the tertiary structure of the O1 protein, as predicted using Phyre2 
software. Figure 13 E depicts frequency of non-pox proteins reported (Phyre2) to share any 





















Table 1. O1 shared sequence identity with protein families and domains 
The O1 peptide sequence (PDB designation: Q80HX1) was analyzed with Phyre2 to determine 
structural homology with proteins of known structure. Table 1 A summarizes the protein 
families reported to be among the top 100 proteins to have any degree of sequence homology. 
Table 1 B summarizes the types of protein domains and structural motifs reported. The number 
of separate structures per domain/family type (# hits), the level of sequence similarity (% 
identity), and the probability that O1 is a structural homolog of these proteins [% confidence, 
(100% maximal)] is listed.  
Table 1 
A           B 
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4.2 Characterization of O1 protein expression during VACV infection 
4.2.1 O1 protein was determined to be approximately 78 kDa 
Polyclonal rabbit sera were raised against two synthetic O1 peptide sequences [(AA351-371 
and AA393-414), Genemed Synthesis]. The two sequences selected consist of relatively 
hydrophilic amino acids (Figure 13 B and C), in order to increase the likelihood of antibody 
epitope availability in both a linear and conformation state. To detect expression of O1, VACV-
WR and ∆O1 infected cell lysates were separated via SDS-PAGE and immunoblots were probed 
with each of the four anti-O1 rabbit sera generated. Initially, none of the sera were able to 
differentiate between bands present within VACV-WR and ∆O1 cell lysates (data not shown), so 
rabbits were boosted with O1 peptides to enhance levels of anti-O1 antibody in sera. Subsequent 
immunoblots revealed a single ~81 kDa band that was present in VACV-WR lysates but not in 
∆O1 lysates (Figure 14 A) or mock-infected controls (data not shown), suggesting the band 
detected within VACV-WR lysates is the O1 protein. Further electrophoresis was performed to 
determine molecular weight more precisely (Figure 14 B), and the O1 band was calculated to be 
~78 kDa. 
4.2.2 Expression of O1 was detected from 3 to 24 h post-infection 
The O1L gene sequence is predicted to contain an early promoter (8), and mRNA has 
been detected as early as three  hours and throughout infection (89). Protein expression was 
examined via immunoblot at various times (3, 6, 8, and 24 HPI). A single O1 band (~78 kDa) 






Figure 14: O1 protein was approximately 78 kDa.  
Polyclonal rabbit antisera were raised against two O1 peptides (351-
LEDILAHIDNARKNSKVSIED-C and 393-LSDIDIKTKIMVLKIVKDWKSC). To detect 
the O1 protein, BS-C-1 cells were equally infected with either VACV-WR (WR) or an ∆O1 
mutant (∆O1-1A1 and ∆O1-3A2). Whole cell lysates were obtained and separated on 4-20% 
SDS-Tris-HEPES gels. All immunoblots performed as described were repeated at least 3 times, 
and representative blots are displayed. 
  







Figure 15. O1 protein expression was detected from 3 to 24 hours post-infection.  
HeLa cells were infected (MOI = 10 for 3 and 6 h; MOI = 5 for 8 and 24 h) with either VACV-
WR (WR) or an ∆O1 mutant (∆O1-1A1 and ∆O1-3A2). Nuclei were isolated, separated via 
SDS-PAGE, and immunoblots were performed using rabbit polyclonal anti-O1 sera. 
Electrophoresis was performed as described at least twice, and representative immunoblots are 






4.3 N-linked glycosylation (NXS/T) is predicted by O1 sequence, but was not 
detected via immunoblot 
The O1 peptide sequence contains numerous predicted glycosylation sites, including five 
N-linked glycosylation motifs (NxS/T, Figure 13). To determine whether O1 is post-
translationally glycosylated, VACV-WR and ∆O1 infected cell lysates were incubated with 
either endoglycosidase H (EndoH), which cleaves the chitobiose core of high mannose and some 
hybrid oligosaccharides, or peptide:N glycosidase F (PNGase), an amidase which cleaves the 
bond between the asparagine residue and the innermost N-acetylglucosamine moiety of high 
mannose, hybrid and complex oligosaccharides. Immunoblot analysis of treated lysates 
demonstrated that B5R, a known N-linked glycosylated VACV protein, was degraded in the 
presence of both EndoH and PNGase F (Figure 16), resulting in several faster migrating 
peptides in the EndoH and PNGase F treated lanes. However, in both EndoH and PNGase treated 
groups, the O1 band resolved as a single band at the same molecular weight (~78 kDa) as in 
untreated lysates. Therefore, no evidence to support N-linked glycosylation of the O1 protein 






Figure 16. N-linked glycosylation of O1 was not detected.  
HeLa cells were infected (MOI = 10 PFU/cell, 12 h) with either VACV-WR or an ∆O1 mutant. 
Whole cell lysates were treated with or without endoglycosidase H (Endo H, top) or peptide:N-
glycosidase F (PNGase F, bottom). Samples were separated via SDS-PAGE and immunoblots 
developed using polyclonal rabbit anti-O1 sera. As a positive control for each sample 
glycosidase digestion, polyclonal anti-B5R sera was used to detect the Vaccinia protein B5R, a 
protein known to be N-linked glycosylated and susceptible to deglycosylation by both EndoH 
(top right) and PNGase F (bottom right).  Immunoblots were performed at least twice and 





4.4 O1 contribution to VACV CPE 
4.4.1 VACV-WR plaques were significantly larger than ∆O1 plaques 
Distinct alterations in ∆O1 plaque morphology (89) appear to mimic characteristics of 
several VACV proteins (reviewed in 141) that promote cytopathic effects but not viral 
replication or morphogenesis. As described previously, this also seems to be the case when O1 is 
removed from the VACV CVA strain. However, this has not been established for O1 deletion 
from the VACV-WR strain. Accordingly, plaque assays were performed to quantify ∆O1 
alterations in plaque morphology. Titration of VACV-WR on BS-C-1 cell monolayers produced 
plaques with approximately 30% larger diameter (Figure 17) than plaques formed in ∆O1-
infected wells. Additionally, clearance from the center of ∆O1 foci was significantly reduced. 
These data support prior studies of O1 mutants in the VACV CVA strain, and indicate that O1 
contributes to VACV CPE in cell culture. 
4.4.2 ∆O1-induced metabolic perturbations significantly differed from those induced by 
VACV-WR only in RAW 264.7 macrophages 
MTS/PMS cell viability assays were performed on several cell lines and isolated primary 
immune cells to address the possibility that cytotoxicity is altered with ∆O1 infection. There are 
two lines of evidence that suggest O1 may affect cytotoxicity: 1) reduced cellular debris 
observed within WR-VACV plaque foci may result from more dead cells being released from the 
matrix; and 2) purported O1 effects on ERK signaling may differentially influence various 
immune cells processes, including cell viability/metabolism. Figure 18 shows that VACV 
infection had minimal effects on the lymphocyte cells tested [i.e. T cells (Figure 18 A and B), 
and B cells (Figure 18 B and C)]. However, in the innate APCs, VACV infection significantly 
reduced metabolism (Figure 19). In immature BMDC and BMDC induced to mature with LPS, 
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the metabolism of VACV-WR and ∆O1 infected cells was similar (Figure 19 A). In RAW 264.7 
macrophages (Figure 19 B), the decline in metabolism was proportional to viral dose in both 
VACV-WR and ∆O1 infections. However, metabolism was further reduced by ∆O1, and this 
was significantly different at the highest viral dose tested. Because the differences noted between 
macrophage metabolism during VACV-WR and ∆O1 infections were statistically significant at 
higher doses, these data may indicate an immune cell type in which O1 is functionally relevant. 
However, since the magnitude of effect was modest, the biological significance remains 
uncertain. 
4.4.3 O1 contributed to VACV induced cell motility 
The migratory potential of infected cells is another component of CPE that influences 
plaque size. VACV-WR promotes migration of infected cells (120, 122), which may enhance 
viral dissemination or immune evasion in vivo. Contributions of the O1 protein to this phenotype 
were assayed using BS-C-1 cells in a wound assay. As shown in Figure 20, uninfected cells 
remained relatively stationary, whereas VACV-WR infected cells migrated into a wound created 
by ‘scratching’ a monolayer of BS-C-1 cells with a pipette tip. VACV-WR infected cells 
migrated maximally between 16 and 24 HPI (Figure 20 B). In contrast, ∆O1 infected cell 
migration was significantly lower (ρ < 0.01) from 16 through 44 HPI. The greatest differences 
between migration effects were observed prior to 24 hours. This reflects prior reports that 
maximal migration of VACV-WR infected cells occurs from 9 to 18 hours post-infection (120). 
Thus, data indicates that the parent VACV-WR infected cells are induced to migrate to a 
significantly greater extent than ∆O1 infected cells. This may suggest that the O1 function 






Figure 17: Plaque size and foci clearance were reduced with ∆O1 infection. 
Plaque morphology was evaluated by the titrating viruses (VACV-WR and ∆O1) on BS-C-1 
monolayers and staining with crystal violet (0.1% in 20% ethanol) 40 HPI. Figure 17 A) Plaques 
formed by 40 HPI were photographed, and the average diameter of plaques formed by each virus 
was determined. Figure 17 B) Plaque sizes are expressed as the mean diameter (mm, n = 10) ± 
standard deviation. * denotes statistical significance, (Student’s t test, ρ ≤ 0.05.)
























Figure 18. No significant differences in lymphocyte viability were detected via MTS assay.  
MTS assays were used as to measure metabolism as an indicator of cell viability. To test whether 
O1 reduces T lymphocyte viability, Jurkat (Figure 18 A) and B04 (Figure 18 B) T lymphocyte 
cell lines were infected in triplicate with VACV-WR or ΔO1 or mock-infected. To test whether 
O1 reduces B cell viability, the 1153 B lymphocyte cell line (Figure 18 C) was infected in 
triplicate with VACV-WR or ΔO1 or mock-infected (media). Purified mouse splenic B cells 
were isolated (EasySep Pan-B negative selection kit), infected as above, and treated with LPS (5 
µg/mL) to induce B cell activation (Figure 18 D). MTS/PMS was added 24 hours post-infection, 
and cellular metabolism was measured (492 nm) as an indicator of cell viability. These 
experiments were repeated at least twice with similar results, and representative data (MOI = 5, 
24 h) are displayed for each experiment. One-way AVOVA revealed no significant differences 
between mock and virus infected cells (Figure 18 A-C), and no statistically significant 
differences among LPS-stimulated cells (Figure 18 D). 
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Figure 19. VACV infection significantly reduced innate APC metabolism, but ∆O1 
infection significantly differed only in RAW 264.7 macrophages.  
(Figure 19 A) C57BL/6 mouse BMDCs cultured for seven days (cRPMI + GMCSF 1.5%) were 
infected in triplicate with either VACV-WR or ∆O1-1A1 (MOI = 5) or mock-infected (media) 
for 3 hours prior to LPS treatment (5 µg/mL). (Figure 19 B) Macrophages (RAW 264.7 cell 
line) were infected in triplicate with either VACV-WR or ∆O1 (MOI = 1, 5, and 10) or mock-
infected (mock, MOI = 0). MTS/PMS was added to culture 24 HPI, and metabolism was 
measured (OD 492 nm) as an indicator of cell viability. Experiments were performed at least 
twice, with similar results.  * denotes significant difference (ANOVA, ρ ≤ 0.05) between 
infection groups and mock infection (MOI = 0). † denotes significant difference (ANOVA, ρ ≤ 
0.05) between VACV-WR and ∆O1. 
 
  














Figure 20. VACV-induced motility was ablated with ∆O1 infection. 
Confluent monolayers of BS-C-1 cells were serum starved for 2 h, then infected with VACV-
WR (WR) or ΔO1 (MOI = 1). After virus adhesion (one HPI), wounds were scratched into the 
cell monolayer with pipette tip. Cells were washed three times, and incubated in serum-free 
media. Wounds were photographed (100X magnification) 0 – 44 HPI. Experiments were 
performed at least 3 times, and representative data are presented. The number of cells that 
migrated into scratch regions (n = 5) were enumerated, and the mean ± standard deviation of 
Figures 20 A and B are indicated in Figure 20 C and D, respectively.  One-way ANOVA was 
















Chapter 5. Discussion 
That the O1 protein regulates the host immune system to promote virulence during 
VACV infection was the major hypothesis tested by this study. This hypothesis was initially 
based on evidence from sequence and literature analysis that the O1L gene is a large gene most 
highly conserved within poxviruses that specifically infect mammals. It is unlikely that 
poxviruses would retain a large gene unless it conferred some survival advantage, either through 
viral multiplication or as a defense against a host. Since O1L is a gene not essential for viral 
replication, it was surmised that this gene, among a number of other possibilities, was retained to 
allow poxviruses to combat the antagonistic environment of a host immune response. 
Furthermore, the levels of O1L gene homology are highest among mammalian-tropic poxviruses, 
compared to poxviruses that infect other host species. Since mammals have a more complex 
adaptive immune system that is lacking in lesser vertebrates, it was hypothesized that the O1L 
gene may more specifically interact with the host adaptive immune response.  
5.1 ∆O1 and VACV-WR immunogenicity   
Investigations into the function of O1 in context of the adaptive immune system 
originated with a survey of the ability of a murine host to initiate a humoral immune response to 
VACV infection in the presence (VACV-WR) or absence (∆O1) of the O1 protein. The humoral 
immune response during ∆O1 infection was enhanced, as evidenced by the substantial increase 
in the level of anti-VACV antibody detected in sera from ∆O1 infected mice compared to 
VACV-WR-infected mouse sera (Figure 7). Although studies have identified O1 as one of 21 
VACV proteins that compose the human antibody response to vaccination with different strains 
of VACV (147), and O1 is one of 19 VACV proteins preferentially targeted by mouse sera (148), 




directly tested. Future experiments should be performed to clarify whether the reduced antibody 
levels detected in sera from VACV-WR infected mice are due to a mechanistic suppression of 
the immune response, or if the reduced signal in the ELISA assays (Figure 7) was due to 
significant levels of O1-neutralizing antibody in vivo. If VACV-specific antibody in the serum of 
VACV-WR infected mice was bound to the O1 protein (not present in ∆O1 infection), this may 
have sequestered antibody available for ex vivo detection via ELISA. Since these observations 
were initially deemed sufficient indication that O1 may interact with the host immune response, 
experiments to define a putative immunoregulatory mechanism were pursued. 
ELISpot assays were performed to elucidate whether T cell responses were affected in 
the same time frame as observed alterations in the humoral response. Cellular responses to 
VACV-WR and ∆O1, as detected by IFN-γ ELISpot, appeared to be similar in magnitude. This 
was surprising, given the number of reported CD4- and CD8-specific epitopes within the O1 
protein (131, 143, 144, 173, 174). These recall responses to VACV antigens were measured 
seven days post-infection, so it is possible that splenocytes at this time had not sufficiently 
expanded in vivo to allow for a detectable difference in VACV-specific recall response to 
VACV-WR and ∆O1 infection ex vivo. Future studies investigating a difference at a later time 
point post-infection (>12 days post-infection) may therefore provide more information of O1 
effects on VACV-specific T cell development in vivo. 
5.2 ∆O1 and ex vivo antibody production 
Given the observed alteration in humoral response, and lack of detectable differences in T 
cell response in vivo, it was hypothesized that O1 may directly influence the ability of B cells to 
produce antibody. Splenocytes from naïve mice that were infected and activated ex vivo with 




reductions induced by both VACV-WR and ∆O1 were similar (Figures 8 and 9). Although LPS 
stimulation was sufficient to induce levels of antibody production significantly greater than 
unstimulated cells, there is the potential that the experimental approach did not accurately reflect 
the mechanisms needed to induce the biologically relevant levels of antibody observed in vivo. 
Since LPS activation of B cells is not the primary mechanism for inducing antiviral antibody 
production during VACV infection, it is likely that ∆O1-infected B cells may still be better 
equipped to mount a humoral response. Optimal production of antibody by B cells in vivo relies 
on a combination of signals, including BCR activation, and T cell dependent stimulation through 
ligation of co-stimulatory receptors and production of cytokines like IL-4. LPS is known to 
stimulate ERK signal transduction (175), so if O1 constitutively sustains ERK activation, it is 
possible for the O1 expressed in VACV-WR infection to functionally synergize with the LPS 
signal, effectively minimizing detectable differences in antibody production between VACV-WR 
and ∆O1. For future studies to confirm that the O1 protein does not directly inhibit B cell 
production of antibody, it would be beneficial to employ an antibody induction assay where B 
cell activation reflects in vivo conditions more closely.  
5.3 Ablated antigen presentation with equivalent T cell activation 
Taking a step back, it was hypothesized that if O1 did not directly affect B cells, O1 may 
modify the global process that precedes humoral immunity – antigen presentation. If appropriate 
interactions between APC and T cells are ablated, any number of subsequent alterations in the 
nature of T cell physiology (i.e. activation, differentiation, or proliferation) or function (i.e. 
cytokine production, etc.) would theoretically result in the reduced antibody production observed 
previously. To preclude interference of T cell specific epitopes present in the O1 protein, the 




infection, ∆O1-infected splenocytes were better activated upon antigenic stimulation, resulting in 
higher levels proliferation by IL-2 dependent CTLL cells. Despite the significant difference 
between the parental infection and the mutant, the magnitude of difference between the two 
viruses was smaller than expected. This small but significant difference was observed 24 HPI 
(Figure 11) through 48 HPI (data not shown), but diminished at later time points. There are 
several explanations that may provide insight for future studies. First, it is possible that, over 
time, excess bioavailable IL-2 was either degraded or consumed by proliferating T cells in 
splenocyte culture, resulting in the inability to detect potentially greater differences in the 
subsequent bioassay. Secondly, although IL-2 containing media was used as a positive control, 
since anti-IL-2 antibodies were not used to confirm that IL-2 was actually contributing to CTLL 
proliferation; it is possible that differences in CTLL proliferation with ∆O1 were due to 
production of another lymphoproliferative cytokine that also promotes CTLL proliferation, but is 
produced in smaller quantities (e.g. IL-4). Additionally, multiple OPXVs encode IL-2 binding 
proteins and decoy IL-2 homologs, including VACV (176). If these VACV IL-2 modulatory 
proteins function in VACV as they reportedly do in other OPXV, this would alter detectable IL-2 
in both virus groups. Since it is unknown how O1 influences the function of other VACV 
proteins, including putative IL-2 regulatory virulence proteins, it is not possible to draw a direct 
association between O1 and IL-2 production with these data.  
Furthermore, Yao et al. reported that lower doses of VACV activate DC better than 
higher doses, and that viral doses >10
-3
 PFU/cell resulted in inhibition of DC maturation (98). 
Since the MOI used (1 PFU/cell) may have been too high, the lower magnitude of difference 
between VACV-WR and ∆O1 would make sense considering DC function may have been 




in vitro (98) compared to BMDC, so the splenocyte culture used for antigen presentation assays 
may have consisted of cells that were more refractory to infection (e.g. SPDC), thus reducing the 
magnitude of antigen presentation observed. Finally, it is conceivable that if O1 function is 
restricted to a specific cell type, the quantity of these putative cells may have been insufficient 
within antigen-activated splenocyte culture to induce a greater measurable difference in antigen 
presentation. 
Since there were multiple observations that antigen presentation was increased in ∆O1-
infected, antigen-activated splenocytes, it was of interest to dissect this system to identify 
putative intercellular and/or cell-specific interactions that may have contributed to these 
differences. Splenocytes that were infected and activated with ConA were assessed via flow 
cytometry to detect expression of the lymphocyte activation marker CD69 on the surface of 
CD4
+





 cells; however, CD69 expression was equivalent between VACV-WR and 
∆O1 infections. The results obtained were similar when ConA was used to activate positively 
selected CD4
+
 splenic T cells that were infected with either virus (data not shown). Since the 
data indicated no difference between VACV-WR and ∆O1 infection in the ability of CD4
+
 T 
cells to express the activation marker CD69, it is more likely that if O1 is indeed affecting some 
aspect of T cell biology, it is a process subsequent to T cell activation. 
5.4 Cell survival and metabolism during VACV infection 
Another method was employed to determine whether ∆O1 functioned in splenocyte 
resident cell types differently than VACV-WR. MTS assays were performed, and focused on cell 
types found in spleen – B cells, T cells, macrophages, and DCs. Since VACV-WR infection is 




be killed with sufficient quantities of VACV-WR. In the T cell lines assayed, doses up to 10 
PFU/cell did not significantly reduce the OD readings in either VACV-WR or ∆O1 (Figure 18 
A). This is not surprising, given that resting T cells are refractory to VACV infection (101, 177), 
and it has been previously reported that high doses of VACV-WR have minimal effects on T cell 
metabolism (99). However, Byrd et al. recently reported that when activated, T cells derived 
from primary human leukocytes become permissive to a complete cycle of VACV binding, 
infection, and replication (177). The lack of VACV membrane receptors on the surface of these 
cultured rodent T cells, as well as an intracellular environment lacking key replication factors, 
are likely explanations for the absence of metabolic effects during T cell infection with either 
virus.  
Similarly, VACV infection had no effects on the metabolism of a murine B cell line or 
purified primary murine splenic B cells, and there were no differences between VACV-WR and 
∆O1 infections. When B cells were treated with LPS (Figure 18 D), the MTS OD significantly 
increased in both virus and mock infected groups. This suggests that LPS treatment increased the 
overall number of B cells in culture, consistent with literature reports that LPS induces B cell 
activation and proliferation (178–181). According to one report, B cells are permissive to VACV 
binding, but not infection (177), so the observation that VACV infection had little effect on B 
cell metabolism/viability suggests that B cells may not have been infected. The question that 
remains is how VACV could reduce antibody production ex vivo, if B cells were not infected. 
Taken together, the ex vivo antibody production and B cell viability assays suggest that VACV 
directly reduces antibody levels, without reducing B cell viability. Future studies should be 




B cells is sufficient to block antibody production, or if antibody produced ex vivo is neutralizing 
VACV in culture, which would explain reduced levels detected via ELISA.  
The ability of VACV-WR to reduce cell viability was observed in the BMDC (Figure 19 
A) and RAW 264.7 macrophage cell infections (Figure 19 B), as doses between 3-5 PFU/cell 
were sufficient for both VACV-WR and ∆O1 to reduce OD. In BMDCs, the addition of LPS also 
enhanced metabolism, although the influence of VACV-WR and ∆O1 infections on metabolism 
was essentially the same. These data suggest that O1 does not influence BMDC metabolism, and 
by proxy, cell viability.  
∆O1-infected macrophages were less metabolically active than VACV-WR infected cells, 
and the magnitude of difference increased with viral dose (ρ > 0.05 at MOI =10, Figure 19 B). 
Since MTS assays are limited to the ability to correlate the metabolic state of living cells present 
in culture, the differences in OD observed could indicate several possibilities, including: 1) ∆O1 
infection reduces the metabolic state of macrophages compared to the parent virus; 2) that ∆O1 
infected macrophages proliferated to a lesser extent, effectively reducing the quantity of 
metabolically active cells, or 3) macrophages remain viable for longer during VACV-WR 
infection compared to ∆O1. The latter two possibilities are not mutually exclusive, however, as 
increased proliferation and sustained viability could occur simultaneously.  
Given any of the circumstances discussed above, a model of the O1 mechanism in the 
context of the macrophage environment might include: enhanced proliferation, metabolism, or 
anti-apoptotic functions. As one example of how this might work: VGF is a homolog of the 
human EGF, and has long been established as a virulence factor that induces cell proliferation 
during VACV infection. Cells in a prolonged proliferative state are thought to provide a 




functions downstream of VGF (89), it is not unlikely that O1 synergizes with VGF signaling to 
enhance cellular proliferation in certain cells. Increased cellular proliferation in VACV-WR 
infected RAW 264.7 cell line would be a simple explanation for why metabolism was greater 
than in ∆O1 infection.  
An interesting proposition is one where O1 concurrently influences: 1) cellular tropism, 
by enhancing infectivity of EGFR-expressing cells, 2) viral dissemination, as motility of VACV-
infected cells enhances viral spread, and infiltration of macrophages into uninfected tissues is 
thought to be one of the primary mechanisms for VARV spread; and 3) immune evasion. If O1 
influences the preference of VACV for infecting anti-inflammatory macrophages (102), this 
would be a stealth mechanism for avoiding early immune detection while the virus waits for 
safer environments to establish infection (e.g. in ovaries). The betaherpesvirus human 
cytomegalovirus (HCMV) has been shown to simultaneously affect the first two possibilities, 
with speculation that the third is also possible (182). Like VACV, activation of EGFR by HCMV 
promotes infection. Chan et al. demonstrated that inhibiting EGFR abrogated HCMV infectivity 
of monocytes, and led them to conclude that EGFR acts as an entry receptor for HCMV. 
Furthermore, EGFR activation promoted monocyte motility and trans-endothelial migration 
during HCMV infection. The demonstration by Chen et al. that these effects were PI3K-
independent was important for establishing that the aforementioned effects occurred subsequent 
to HCMV glycoprotein B (gB) activation of EGFR. HCMV gB induction of EGFR activity is 
functionally orthologous to VACV C11, including anti-apoptotic functions. It would be 
interesting to determine whether the HCMV manipulates ERK downstream of EGFR to 




possible that there is some betaherpesvirus protein that is functionally orthologous to O1, which 
bears further study. 
Upon demonstrating that ERK activation and plaque sizes were equivalent in CVA and 
CVA-∆O1 infected, ERK inhibitor-treated chick embryo fibroblast cell line, but significantly 
different in a number of other cell lines tested, Schweneker et al. surmised that O1-sustained 
activation of ERK clearly depends upon cell type (89). Whether O1 functions similarly in 
macrophages (i.e. by sustaining ERK activation) remains to be established. If so, it is 
conceivable that this would provide an experimental model in which to study the O1 functional 
phenotypes observed to date in a single, biologically relevant, environment. Finally, since the 
ERK/MAPK signal cascades are also known to regulate metabolism, apoptosis, and macrophage 
differentiation, whether O1 has any functional significance in these contexts will be of great 
interest.   
5.5 ∆O1 plaque and cell migration phenotypes 
Another aspect of this study was to evaluate O1 behavior in cell culture. Investigations 
were initiated on two levels: 1) determine a mechanism whereby O1 influences CPE; and 2) 
characterize the O1 protein to understand how the structural biology of this pox virulence protein 
lends itself to novel functions.  
 Prior reports (89) showed that CVA-∆O1 formed plaques that were up to 50% smaller in 
some cell types. It was of interest to quantify similar effects with the VACV-WR strain and ∆O1. 
Although predecessors in the laboratory where these studies were performed reported little to no 
difference between VACV-WR and ∆O1 plaque sizes (168), the data reported herein 
demonstrate a 30% reduction in the diameter of ∆O1 plaques formed on BS-C-1 cell monolayers. 




agreement with Schweneker et al. Furthermore, data collected by predecessors to this study 
demonstrated equivalent levels of VACV-WR and ∆O1 replication and spread in single and 
multi-step growth analyses. Taken together, these results suggest that O1 may be classified 
among an emerging group of plaque phenotype-modulating proteins that affect cell morphology 
but not viral life cycle (113).  
 One of the proteins in the aforementioned group, F11, has been shown to similarly 
enhance VACV plaque size, and subsequent studies have demonstrated that F11 promotes the 
motility of VACV-infected cells (122, 124, 183). Thus, it was hypothesized that O1 may 
influence VACV-WR induced cellular migration. Indeed, VACV-WR infected cells were 
significantly enhanced in their migratory capacity compared to ∆O1 infected cells. The greatest 
magnitude of VACV-WR induced cellular migration into a monolayer wound occurred between 
0 and 16 HPI, which closely reflects prior kinetic studies demonstrating that VACV-induced 
migration occurs maximally 10-14 HPI (120). Furthermore, Sanderson et al. also reported that 
early VACV gene expression was necessary and sufficient to induce cell migration, but not 
formation of cellular projections (120). This supports a role for O1 in the temporal regulation of 
VACV-WR induced migration, since O1 is expressed early and the increased cell migration of 
VACV-WR infected BS-C-1 cells was within established kinetics. Interestingly, in recent 
observations of RAW 264.7 macrophages, there appeared to be distinct cellular projections in 
VACV-WR infected cells that were not present with ∆O1 infection at 16 HPI (data not shown). 
Byrd et al also recently published similar observations that VACV alters macrophage CPE at 16 
HPI (102). Although these preliminary data are informative, to further explore the role of O1 in 
cell migration, and whether VACV-WR infection induces migration of macrophages and 




data provide strong evidence to suggest that O1 promotes migration of VACV-WR infected 
cells, which may contribute to the expanded plaque size during VACV-WR infection. 
5.6 Structural characteristics of the O1 protein 
 Finally, knowledge of the structural biology of O1 has been limited to analysis of DNA 
and peptide sequences to uncover protein homology and predict functional motifs (89, 139, 160), 
or PCR analysis of mRNA expression (8, 89). Given that the majority of gene functions depend 
upon protein structure, the O1 protein was characterized to determine 1) if the O1 protein was 
expressed; 2) whether the protein size was as the amino acid sequence predicted or if cell-
dependent modifications (e.g. predicted N-linked glycosylation motifs) were functional; and 3) 
relative expression kinetics. Rabbit sera raised against two separate O1 peptides sequences used 
in immunoblot analyses detected a protein band of ~78 kDa that was present in VACV-WR 
infected cell lysates but not in ∆O1 lanes (Figures 14-16). These data are the first reported 
studies detecting the O1 protein expression during VACV-WR infection.  
 Although the O1 protein band detected was equivalent to the size predicted based on the 
peptide sequence, it is possible that this same size range would also be observed if the O1 protein 
undergoes cleavage and post-translational modification following expression. With at least five 
putative N-linked glycosylation motifs in the O1 sequence, it was of interest to determine 
whether O1 was, in fact, N-linked glycosylated. Two enzymes that cleave glycosylation moieties 
at different positions were used, but the O1 band did not migrate differently upon enzymatic 
treatment, suggesting that the O1 protein is not N-linked glycosylated. This is not surprising, 
given the early expression and activity kinetics of O1. If glycosylation did occur, the O1 
functional kinetics would rely upon cellular processes, and the time required to traffic through 




infection (8, 89), and RAF/MEK/ERK phosphorylation is reduced with ∆O1 infection within 30 
minutes (89), it is questionable whether any post-translational modifications occur prior to O1 
function. This is not to say that later modifications do not occur; however, data obtained from 
cellular lysates 8-10 HPI (Figures 15 and 16) indicate that N-linked glycosylation is not among 
them. Furthermore, the O1 band migrates to the same ~78 kDa range from 3 through 24 HPI 
(Figure 15), suggesting that any protein modifications that may occur would be minimal. Since 
many VACV proteins that are highly glycosylated are expressed later and are membrane 
associated, the absence of N-linked glycosylation argues against possible integral membrane 
localization for O1. Additionally, since ERK is mainly cytoplasmic until activated, and O1has 
been speculated to function upstream of RAF, it could be inferred that O1 is a soluble 
cytoplasmic protein. Taken together, these findings are the first to show that O1 is expressed as a 
78 kDa protein that lacks N-linked glycosylation modifications. 
 Finally, Phyre2 software was used to generate a 3D model of the O1 protein based on the 
amino acid sequence. The homology of the protein structure generated ab initio was compared to 
previously modeled proteins reported in PDB (Table 1). Ab initio modeling is notoriously 
imprecise, so it is unsurprising that reported structural homology to the O1 protein (of which 
little is known) was given low confidence scores. However, proteins from different species can 
share low sequence similarity, yet be functional orthologs; therefore, these findings were given 
due consideration.  Interestingly, low levels of sequence identity with O1 (5 – 30%) were shared 
among a number of protein families with functions ranging from bacterial toxins to mammalian 
enzymes involved in DNA replication. Since O1 contains a predicted DNA binding domain, it 
was unsurprising that there were a number of proteins associated with DNA replication. 




unlikely that O1 functions within this realm. On the other hand, the putative O1 nuclear 
localization signal (NLS) is interesting in the context of ERK signal cascade, since ERK is 
known to translocate to the nucleus upon activation. Whether the predicted O1 NLS is 
functional, and whether this has any bearing on ERK activity during VACV infection would be 
useful to know, as nuclear translocation by a virulence protein would be a completely novel 
signal cascade manipulation for poxviruses.  
The sequence identity to various lyase domains, although limited, is also of significant 
interest, since it has been shown that the HMG CoA lyase indirectly regulates B-RAF mediated 
cell proliferation (184). Additionally, ATP citrate lyase, which functions downstream of HMG 
CoA lyase, has also been implicated in EGF-initiated MAPK-mediated anti-apoptotic signaling 
(185). It could therefore be possible that O1 functions as a lyase to enhance ERK activation. O1 
also had a putative thioredoxin-like fold. Thioredoxins negatively regulate signaling of apoptosis 
signal-regulating kinase (ASK) through direct binding (186). Thioredoxin overexpression 
elevates ERK phosphorylation (187), and thioredoxin knockdown inactivates EGF-induced ERK 
activation (188). Since all known VACV apoptosis regulators are inhibitory (189), it would be 
interesting to determine whether O1 moderates pro-apoptotic stress responses in order to 
maintain the cell viability needed for VACV infection. 
O1 also exhibited low levels of predicted structural homology to the ligase family of 
proteins, with multiple E3 ubiquitin ligase homologs represented. Ubiquitin ligases target 
proteins for degradation, and it has been shown that an E3 ubiquitin ligase targets the ERK 
phosphorylase MKP-1 (190). Since MKP-1 downregulates ERK, inhibition of this negative 
feedback regulator would be one method that O1 could employ to sustain VGF-mediated 




likely that O1 activity influences the function of H1, so it will be important to determine if O1 
functions in tandem with this protein. 
Since O1 is such a large protein, it is possible that the shared sequence identity with 
smaller proteins is not as low as predicted. Given that enzyme active sites don’t encompass the 
entirety of a protein, and proteins can have a number of active sites with different functions, it is 
possible that there may be more than one functional ortholog among the protein families 
discussed. Although many of the protein domains discussed exhibited lower levels of structural 
homology to the O1 protein, there are some poxvirus proteins that have been demonstrated to 
function similarly to homologous proteins with as little as 25% sequence similarity (138, 192), so 
there is some relevance to these considerations. Overall, these predictions may provide 
mechanistic insight into the O1 functions observed, and provide targets when designing future 
studies.  
5.7 Implications for biotherapeutics 
In less than a century, the poxvirus field has progressed beyond desperation to eradicate 
the scourge of smallpox to the ability to actually use sister OPXV viruses to treat many other 
human menaces, from cancer to Ebola virus. In the context of these studies to understand the role 
of O1, the alacrity in which novel foundational research into O1 has been translated into a 
functional treatment for cancer is especially noteworthy. When Schweneker and colleagues first 
published data on O1 in 2012, there was minimal interest in continuing research on a protein that 
behaved contrary to expectation, and the project was discarded by that group (personal 
communication, 2014). As the research in this report was ongoing, Nakamura et al. (164) were 
able to utilize the expanded catalogue of poxvirus information provided by Schweneker, and a 




concept was that enhanced cell proliferation promotes efficient VACV infection, so removing 
VGF and/or O1 would only allow efficient VACV replication in cells where basal 
RAF/MEK/ERK is elevated. In this case, tumor cells become the only proliferative environment 
for VACV, so the tumor cells that are targeted for VACV multiplication are subsequently lysed 
upon resolution of viral life cycle. Thus, VGF-/O1- virus use to preferentially target tumor cells 
for oncolysis was experimentally tested, and received patents worldwide in 2016. Given the 
laudable accomplishments that have employed established phenotypes in the absence of O1, it 
will be of great importance in the future to differentiate this from what happens when O1 is 
present.  With certain classes of poxvirus virulence proteins (cytokine inhibitors/mimics, 
complement inhibitors, protease inhibitors) having been tested individually in the absence of 
virus for their potential as novel biotherapeutics (67), it is conceivable that the O1 protein may 




Chapter 6. Key Findings and Conclusions 
Because the O1 protein is most highly conserved by poxviruses that infect mammals, but 
is not essential for the viral life cycle, it was hypothesized that the O1 protein may be retained by 
mammalian-tropic poxviruses in order to combat the host immune response. Mice were infected 
with the VACV Western Reserve strain (VACV-WR) or with VACV-WR virus lacking the O1 
protein (∆O1), and higher levels of VACV specific antibody were detected in sera from ∆O1-
infected mice. However, VACV-specific T cells from mice infected with either virus were 
reactivated equally ex vivo. To determine if VACV-WR directly ablated antibody production, 
murine splenocytes and primary B cells infected with VACV-WR and ∆O1 infection were 
examined ex vivo for their ability to produce antibody. Infection with both viruses reduced 
antibody levels equally, suggesting that alterations in antibody levels during ∆O1 infection may 
occur through an indirect mechanism.  
VACV inhibition of antigen presentation is a mechanism that indirectly reduces antibody 
production in vivo, therefore the influence of VACV-WR and ∆O1 infection on the ability of 
antigen-stimulated mouse splenocytes to present antigen and subsequently induce T cells to 
produce interleukin-2 (IL-2) was tested ex vivo. Compared to VACV-WR, ∆O1-infected 





) did not increase with ∆O1 infection, suggesting that the improved antigen 
presentation noted with ∆O1 infection may not occur at the level of T cell activation. Taken 
together, it appears that ∆O1 infection increases immunogenicity but may not directly enhance B 
or T cell activity. 
O1 purportedly enhances MAPK signal transduction, the functional relevance of which is 




immune cell types. Of the adaptive (e.g. T and B lymphocytes) and innate [e.g. DCs and 
macrophages] immune cells examined for differences in cell viability, the macrophage cell line 
was the only one found to be differentially affected by VACV-WR or ∆O1 infection, signifying 
that macrophages may be a biologically relevant immune cell in which O1 functions.  
Plaque assays were performed to investigate the contribution of O1 to VACV CPE in cell 
culture. VACV-WR plaques were significantly larger than ∆O1, supporting prior reports of 
reduced CPE with another VACV strain lacking O1. VACV-induced cell migration contributes 
to CPE, so it was hypothesized that O1 may enhance migration during infection. Cellular 
migration was significantly delayed with ∆O1 infection, whereas VACV-WR infected cells 
migrated optimally as previously reported.  O1 effects on migration may be an important 
mechanism for virulence in vivo, especially if O1 functions similarly in an immunologically-
relevant cell type. 
Expression of O1 has been detected between three and 24 hours post-infection. Despite 
numerous NxS/T motifs, N-linked glycosylation of the O1 protein was not detected. Analysis of 
the O1 secondary structure revealed a number of proteins with low levels (5 – 30%) of sequence 
identity. Although several pox proteins reportedly have low sequence identity with their 
functional orthologs, the low levels of structural homology detected suggest that the O1 protein 
structure is unique to poxviruses, and may have a completely novel functional mechanism. 
In summary, this work has revealed novel properties of O1 biology, and provided data 
suggesting that the immunogenicity of the VACV-WR strain can be increased by the removal of 
O1. Data support prior reports that O1 function may be cell type dependent, as results showed 
that RAW 264.7 macrophage cell line was the only one tested where metabolic activity, and 




data may provide a biologically relevant immune cell type in which O1 functions optimally to 
promote virulence in vivo. The influence of the VACV O1 protein on enhancing virally-induced 
cellular migration provides insight into how VACV-WR causes CPE in vitro, which may provide 
a foundation for future studies that seek to clarify potential associations between plaque 
phenotype with poxvirus virulence mechanisms in vivo. Finally, the function of the VACV 
virulence protein O1 has been of significant interest in emerging oncolytic vectors, so any 
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